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ABSTRACT 
A note to the reader: Portions of this abstract have been previously published in 
the journals PLoS One, McGraw et al. 2012. 7(4):e34477, Blood, Basiorka et al. 
2011. 118:2382a, and Blood, Basiorka et al. 2012 120(21):3455a, and have been 
reproduced here with permissions from the publishers. 
 
 Myelodysplastic syndromes (MDS) include a spectrum of stem cell 
malignancies characterized by ineffective hematopoiesis and predisposition to 
acute myeloid leukemia (AML) transformation.  Patients are predominantly older 
(greater than 60 years old), with progressive cytopenias resulting from ineffective 
and cytologically dysplastic hematopoiesis.  MDS subtypes are classified by 
morphologic features and bone marrow blast percentage, as well as cytogenetic 
pattern, as is the case for deletion 5q MDS.  Interstitial deletion of the long arm of 
chromosome 5, del(5q), is the most common chromosomal abnormality in 
patients with MDS, and the 5q- syndrome, represents a distinct subset of del(5q) 
MDS characterized by an isolated deletion, megakaryocyte dysplasia, 
hypoplastic anemia, and an indolent natural history.  MDS risk stratification is 
most commonly based on the International Prognostic Scoring System (IPSS) 
with survival outcomes ranging from a few months to many years based on risk 
factors.  There are several therapeutic options for MDS including hematopoietic 
growth factors, immunosuppressive therapy, azanucleosides, and allogeneic 
stem cell transplant, however, there is still a need for more effective treatment 
ix 
 
options, particularly targeted therapeutics.  One of the most effective treatments 
for MDS is selective for del(5q) MDS, and is the second generation 
immunomodulatory agent, lenalidomide (LEN).  
 LEN is an analog of the known teratogen, thalidomide, and has broad 
biological effects including selective cytotoxicity to del(5q) clones, activation of T-
cells, and expansion of erythroid precursors.  In patients with del(5q) MDS, LEN 
is effective in up to 75% of patients, however, 50% of patients will become 
resistant within 2-3 years of treatment response.  Studies in normal 
hematopoietic progenitors have shown that LEN induces expansion of the 
primitive erythroid precursors, which our laboratory has shown is accompanied 
by sensitization of progenitors to ligand induced erythropoietin receptor (EpoR) 
signaling.  This sensitization is evidenced by increased and prolonged activation 
of the Signal Transducer and Activator of Transcription 5 (STAT5), compared to 
Epo stimulation alone.  Although EpoR signaling is augmented by LEN, the exact 
mechanisms by which this is mediated to result in erythroid expansion are not 
fully characterized.  In del(5q) MDS, we have shown that LEN selectively 
suppresses del(5q) clones via inhibition of the haploinsufficient phosphatases 
Cdc25c and PP2a, as well as stabilizing the human homolog of the murine 
double minute-2 protein (MDM2) to decrease expression of the tumor suppressor, 
p53, however, the mechanisms of action of LEN in non-del(5q) MDS remains 
elusive. 
   Although most anemic MDS patients have normal or elevated endogenous 
levels of Epo, as well as comparable levels of progenitor EpoR density relative to 
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healthy individuals, the biologic pathology underlying the impaired EpoR 
signaling in MDS is poorly defined.  Recent reports have shown that membrane 
microdomains are important for T-cell, c-kit, and integrin signaling, however, 
there have been no reports on EpoR membrane localization.  Lipid rafts are 
discrete membrane entities that provide platforms by which receptors aggregate 
and initiate downstream signaling.  Furthermore, reports have indicated that 
there is a decrease in lipid raft density in GM-CSF primed MDS neutrophils, that 
consequently impaired production of reactive oxygen species (ROS) after fMLP 
stimulation, suggesting a role of rafts in MDS disease biology.  Based on the role 
of rafts in signaling, and potential role in MDS pathogenesis, we sought to 
determine whether there was specific membrane localization of EpoR to the raft 
fractions, and whether disruption of rafts in MDS erythroids could impair EpoR 
signaling.  To address this, we first examined the membrane localization of EpoR 
on the cell surface.  We show here that EpoR translocates to lipid rafts in both 
erythroid progenitor cell lines as well as primary progenitor cells after stimulation 
by Epo.  Furthermore, we found that Epo stimulation increases the assembly of 
lipid rafts, as well as the aggregation of rafts on the cell surface.  Epo stimulation 
not only promoted the recruitment of EpoR into the raft fractions, but also 
downstream signaling intermediates such as Janus kinase 2 (Jak2), STAT5, and 
Lyn kinase.  Moreover, a negative regulator of EpoR signaling, the CD45 tyrosine 
phosphatase, was redistributed outside of raft fractions after Epo stimulation, 
potentially enhancing receptor signal competence.  Furthermore, disruption of 
lipid rafts by depletion of membrane cholesterol with MβCD (methyl-β-
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cyclodextrin) inhibited EpoR signaling in both cell lines and primary bone marrow 
progenitor cells.  Additionally, we found that inhibition of Rho-associated, coiled-
coil containing protein kinase (ROCK) and/or Ras-related C3 botulinium toxin 
substrate 1 (Rac1), blocked the recruitment of the receptor into the raft fractions 
indicating a critical role of these GTPases, and associated proteins, in the 
transport and localization of EpoR into raft microdomains. 
 We next asked whether LEN could alter lipid raft assembly in erythroid 
precursors in the absence of Epo.  LEN not only induced raft formation and 
aggregation but also increased F-actin polymerization.  Similar to Epo stimulation, 
LEN alone was able to induce the recruitment of EpoR, Jak2, and STAT5 into raft 
fractions.  Additionally, CD45 was redistributed outside of raft fractions after LEN 
treatment.   Similarly, inhibition of ROCK blocked LEN induced raft formation and 
F-actin polymerization, indicating that LEN utilized effectors shared by Epo.  
Furthermore, LEN was able to increase raft density in raft deficient primary MDS 
erythroid progenitors.  These data demonstrate that LEN may enhance erythroid 
expansion via induction of EpoR signaling competent raft platforms, to enhance 
survival and differentiation transcriptional response.       
 Recently, ribosomal protein (RP), S-14, gene (RPS14) haplodeficiency 
was found to be a key determinant of the hypoplastic anemia in del(5q) MDS.  
Allelic loss of RPS14 compromises ribosome assembly, thereby causing 
nucleolar stress and release of free RPs that bind to and promote the 
degradation of MDM2, the principal negative regulator of p53.  As a result, the 
accumulation of RPs causes lineage restricted stabilization of p53 in erythroid 
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precursors.  Our laboratory and colleagues confirmed that cellular p53 
expression levels were elevated in del(5q) erythroid precursors, and that LEN 
decreased expression in responding patients.  However, at the time of LEN 
treatment failure, p53 expression was again elevated at levels exceeding those 
at baseline.  These results suggest that LEN is initially able to reverse p53 
accumulation levels and that this action may be a mechanism by which LEN is 
selectively cytotoxic to del(5q) clones.  Subsequent studies showed that LEN 
inhibits the cereblon E3 ubiquitin ligase complex, the newly discovered target of 
LEN.  Cereblon has been reported to be the principal protein involved in 
thalidomide induced teratogenicity.  Furthermore, the cytotoxic activity of LEN in 
multiple myeloma is dependent on cereblon.  Our laboratory found that LEN 
inhibits the auto-ubiquitination of MDM2, thereby stabilizing the protein, and 
promoting ubiquitination of and ultimately the degradation of p53.  Additionally, 
we found that LEN blocked the binding of free ribosomal proteins to MDM2, 
which are liberated from the nucleosome by ribosomal stress from RPS14 
haploinsufficiency, consequently stabilizing the E3-ubiquitin ligase and fostering 
p53 degradation.    
 In non-del(5q) MDS there is no cytotoxicity of MDS clones by LEN, 
suggesting an alternative method of erythropoiesis rescue.  Although we know 
that LEN promotes the formation of signaling platforms, and recruitment of EpoR, 
we wished to determine whether there was an effect of LEN on EpoR expression, 
as EpoR expression is controlled through ubiquitination and proteasomal 
degradation.  Treatment of erythroid progenitor cell lines and primary erythroid 
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precursors with LEN increased cellular expression of Jak2-associated EpoR in a 
concentration dependent manner.  There was no change in mRNA expression, 
supporting a post transcriptional mechanism.  We then investigated whether 
receptor up-regulation was limited to EpoR, or included other cytokine receptors.  
We found that LEN induced expression of another Jak2 associated Type I 
receptor, IL3-R, but did not alter cellular expression of c-kit, a Type II cytokine 
receptor.  Because Type I cytokine receptor turnover is regulated by a shared 
E3-ubiquitin ligase, and LEN inhibited both MDM2 and cereblon, we evaluated 
the effects of LEN on the E3-ubiquitin ligase, Ring Finger Protein-41 (RNF41), 
which regulates steady state or ligand independent, Jak2 associated Type I 
receptor internalization.  We found that LEN inhibited the ubiquitination activity of 
RNF41, ultimately stabilizing EpoR membrane residence and increasing 
expression. 
 In summary, MDS patients display ineffective hematopoiesis likely in part 
to decreased lipid raft assembly.  Stimulation by Epo, or treatment by LEN, not 
only induced raft formation, but also induced the recruitment of both growth factor 
receptor, and downstream signaling intermediates into raft fractions to enhance 
EpoR signal fidelity.  We have shown here two methods by which LEN may 
augment EpoR signaling.  First, LEN increases lipid rafts and promotes 
recruitment of signaling effectors.  Second, LEN increases and stabilizes the 
expression of EpoR through inhibition of the E3 ubiquitin ligase, RNF41.  
Therefore, we suggest here that LEN may have broad E3 ubiquitin ligase 
inhibitory effects.  These data also indicate that lipid raft upregulation by LEN is 
xiv 
 
mediated through GTPases, suggesting that GTPase activation may also occur 
via inhibition of specific E3 ubiquitin ligases, a question to be addressed in future 
studies.  
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CHAPTER 1 
Background 
 
Myelodysplastic Syndromes (MDS) 
 
 MDS Overview.  Myelodysplastic syndromes (MDS) are a heterogeneous 
group of stem cell disorders characterized by ineffective hematopoiesis and 
predisposition to acute myeloid leukemia (AML) transformation.  Pathobiological 
features of MDS include upregulation of inflammatory response genes and 
corresponding cytokine production that contribute to accelerated apoptotic death 
of hematopoietic progenitors with consequent ineffective hematopoiesis which 
underlies the cytopenias characteristic of MDS.1  MDS is observed primarily in 
older individuals (greater than 60y) and overall survival ranges from as short as a 
few months to several years based on a number of disease features detailed 
below.  Although there are instances of familial MDS, these cases are rare and 
have been linked to mutations in particular genes such as RUNX1.2  MDS also 
occurs in children, although rarely, and is often associated with constitutional 
genetic disorders or inherited bone marrow failure syndromes.3  The prevalence 
of MDS is greater in males than females, and is observed more frequently in 
patients previously exposed to toxic agents, such as chemotherapy or radiation.4  
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Recent reports suggest that there are up to about 75 per 100,000 new MDS 
cases diagnosed each year in the US among individuals 65 years of age or 
older.5 
 
 MDS classification.  Distinction of MDS subtypes utilizes the subjective 
morphologic characterization of cytological dysplasias that was first defined more 
than 30 years ago.6-8  MDS subtypes were initially characterized according to the 
French-American-British (FAB) classification for MDS that was developed in 
1982.9,10  A diagnosis of MDS by the FAB classification was strictly based on cell 
morphology and bone marrow blast percentage; however, considerable 
prognostic overlap between subtypes and a surge of data on disease biology 
generated the need for a new classification system.  In 2001, the World Health 
Organization (WHO) established a new classification that further refined 
subtypes, reorganized previous classifications, and added additional categories.8-
11
  The WHO classification was also based on morphology and blast counts, 
however, a single chromosomal aberration, del(5q) was introduced into the 
diagnostic criteria.  The 2001 WHO classification implemented discrimination 
based on the number of lineages of cytological dysplasia and introduced the 
RCMD (refractory cytopenia with multilineage dysplasia) subtype, either with or 
without ring sideroblasts (RS).  The WHO also lowered the blast threshold for 
AML from 30% to 20%, and moved chronic myelomonocytic leukemia (CMML) 
into a new category of MDS/MPN (myelodysplastic myeloproliferative 
neoplasm).8-10,12  Additionally, a new category was added, the 5q- syndrome, a 
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subtype characterized by less than 5% bone marrow blasts and an isolated 
chromosome 5q deletion.8,12  Detailed discussion of the 5q- syndrome will be 
provided in the next section.   
Although the 2001 WHO was widely accepted, modest changes were 
recommended to this classification system in 2008.8,11,13  The 2008 WHO 
classification is still based on cellular morphology, blast percentage, and 
cytogenetics, but provides a more detailed subtyping system.8,11  Most notable of 
the revisions include reorganization of refractory cytopenias with unilineage 
dysplasia (RCUD) into lineage specific subtypes, extension of the description of 
MDS-U (unclassified), changing the 5q- syndrome to del(5q) MDS, and addition 
of refractory cytopenias of childhood (RCC).8,11-13  Undoubtedly, as new data 
emerges and new techniques provide more pathobiologic data, revisions will 
likely be needed to further elucidate distinct subtypes of MDS based upon 
biological drivers.  A summary of the FAB and WHO classifications is provided in 
Table 1. 
 
5q- Syndrome.  Approximately 50% of patients with MDS carry a 
chromosomal abnormality.14,15  The most common chromosomal abnormality 
found in up to 25% of MDS patients, is interstitial deletion of part of the long arm 
of chromosome 5 [del(5q)].1,16,17  In 1974, Van den Berghe and colleagues first 
described this distinct hematological subset of MDS patients and coined the term 
5q- syndrome18,19  Patients with 5q- syndrome have severe hypoplastic anemia  
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Table 1.  Comparison of MDS classifications according to the French-American-
British (FAB) and World Health Organization (WHO) classifications. 
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leading to transfusion dependence, accompanied by mild leukopenia, normal or 
elevated platelet counts, and atypical bone marrow megakaryocytes.  In 2001, 
the WHO created a separate MDS subtype called the 5q- syndrome that required 
the presence of isolated del(5q) chromosomal abnormality and bone marrow 
blasts less than 5%.  There is a higher prevalence of the 5q- syndrome in 
females compared to males (7:3) and these patients have better predicted overall 
survival and decreased risk for leukemic transformation.16,20,21  Nevertheless, 
overall prognosis in the 2001 category of 5q- syndrome was heterogeneous 
because of the inclusion of atypical cases with thrombocytopenia or neutropenia.  
For this reason, the WHO change the terminology to del(5q) MDS in 2008.  The 
presence of a single cytogenetic abnormality provides the opportunity for 
researchers to study the pathogenesis of this one subtype of MDS, an effort often 
complicated by the vast heterogeneity of other subtypes.  Mapping of the 
commonly deleted region (CDR) in the 5q- syndrome revealed an area of 1.5 
megabases comprised of 41 genes located at 5q32-33.20,22  Although initial 
studies sought the identification of a tumor suppressor gene that could be linked 
to disease development, these efforts were unsuccessful.  It was only recently 
that one specific gene in the CDR, RPS14, has been linked to the pathogenesis 
of the hypoplastic anemia found in del(5q) MDS.23  Ebert et al. performed a 
series of elaborate knockdown experiments, and showed that only shRNA 
knockdown of RPS14 was able to recapitulate the 5q- phenotype, i.e. erythroid 
specific proliferative arrest and apoptosis indicating its importance in the 
pathobiology of this disease.23  Haploinsufficiency for RPS14 disrupts ribosome 
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assembly causing ribosomal stress, and as in congenital ribosomopathies, 
activates p53 in erythroid precursors causing hypoplastic anemia. Further 
discussion of ribosomopathies and the 5q- syndrome will follow under the 
Ribosomopathies section of this manuscript. 
  
International Prognostic Scoring System (IPSS).  Although the WHO 
classification system takes into account morphological, cytological, and a single 
cytogenetic feature, it lacks other key prognostic variables, and for that reason 
risk stratification is accomplished primarily through the International Prognostic 
Scoring System (IPSS) which was published in 1997.24  The IPSS divides 
patients into four distinct categories; low risk, intermediate-I, intermediate-II, and 
high risk disease.24-27  Overall survival and AML transformation risk increases 
with risk prognostic score and category, with the median survival for untreated 
patients with low, Int-1, Int-2, and high risk disease of 5.7, 3.5, 1.2, and 0.4 years, 
respectively.12   
The IPSS is calculated based on three parameters; bone marrow blast 
percentage, number of cytopenias, and karyotype as summarized in Table 2.9,25-
27
  Each parameter is assigned a particular weighted score which are then 
summed to give the cumulative score representative of a particular risk category. 
The values for each parameter are also provided in Table 2.  Although the IPSS 
was developed based on a data set of approximately 800 patients from the US, 
Europe, and Japan, the large amounts of data generated since 1997 has led 
some to believe a revision of the IPSS was necessary.27  In 2012, the revised 
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IPSS, IPSS-R, was published by Greenberg and colleagues.24  The IPSS-R was 
based on a significantly larger cohort of patients (IPSS, n= 816; IPSS-R, n=7012) 
yet still utilized the same three clinical characteristics of the original IPSS, 
including number of cytopenias, bone marrow blast percentage, and karyotype.24  
The major changes in the revised system include revised bone marrow blast 
percentage categories, grading the severity of each cytopenia, expansion of 
chromosomal abnormalities captured, and an increase in the diagnostic 
parameters taken into account, such as age, serum ferritin, and lactate 
dehydrogenase (LDH).  Notably, the IPSS-R has 5 risk categories and 5 
cytogenetic risk categories as opposed to four and three in the original IPSS, 
respectively.24  The IPSS-R was published in September of 2012; however, at 
the time of this manuscript, the IPSS is still the most commonly used prognostic 
scoring system by clinicians.  Although, the IPSS is the most commonly used 
system, it should be noted that there are other proposed risk stratification 
systems for MDS such as the WHO classification-based Prognostic Scoring 
System (WPSS).28  The WPSS takes into account WHO morphologic subtypes 
as well as transfusion dependence, and consists of 5 distinct risk categories 
including very low, low, intermediate, high and very high risk categories.28,29  The 
most notable characteristic of the WPSS is the effectiveness of determining 
prognosis at any time point during the disease, allowing for real time treatment 
decision making at any time in the disease natural history.27-29  Yet another 
scoring model published in 2008, is the MD Anderson Prognostic Scoring System 
(MPSS).30,31  A major component of this system is that disease duration and    
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Table 2.  International Prognostic Scoring System (IPSS) of MDS 
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previous therapies are taken into account, however, it does not consider bone 
marrow blast percentage (below 30%) or WHO classification.30,31 
 Although there are several scoring systems available for risk stratification 
in MDS, reports continue describing novel prognostic variables.  Some such 
variables include β2-microglobulin, bone marrow fibrosis, hypoalbuminemia, and 
others.32  It should also be noted that some of these systems, in particular the 
IPSS, are limited in their effectiveness due to the heterogeneity within each 
subgroup, particularly with respect to the high proportion of normal karyotype 
assessed by metaphase cytogenetics.33  Currently, new molecular biomarker 
approaches are being proposed including use of single nucleotide polymorphism 
(SNP) arrays (SNP-A) or exome sequencing to identify very small genetic lesions 
not resolved by metaphase cytogenetics.33  It reasons then, that these scoring 
systems will continue to evolve to better delineate risk based on biological 
features.  
 
MDS treatment.  Often the first treatment for management of anemia in 
patients with MDS, particularly lower risk MDS, is the use of erythroid stimulating 
agents (ESAs) such as recombinant erythropoietin (Epo), either alone or in 
combination with granulocyte/macrophage colony stimulating factor (GM-CSF), 
or granulocyte colony stimulating factor (G-CSF).4,34  The use of ESAs grew in 
popularity in the early nineties; however, response rates were not robust.  Initial 
reports of erythroid response rates to Epo ranged from about 10-20%.34,35  With 
development of response predictive models, the rates of response to Epo have 
10 
 
risen with proper patient selection, however, they remain relatively low (30-60%) 
and differ greatly between studies and institutions.4,36  A relatively new approach 
to treating myelodysplastic syndromes is the use of immunosuppressive 
therapies (IST) such as cyclosporine, and ATG (anti-thymocyte globulin).4,37,38  
These treatments have had greater success inducing effective hematopoiesis in 
younger patients with lower risk disease, however, response rates again vary 
greatly from center to center.4  Current studies are underway trying to delineate 
those patients expected to respond to IST based on CD4/CD8 ratios or other 
biomarkers.38   
  Another class of MDS therapeutics, the azanucleosides, includes two of 
the three currently Food and Drug Administration (FDA) approved therapies for 
MDS, azacitidine and decitabine.4,37  The azanucleosides are believed to target 
the DNA hypermethylation observed in MDS patients.  This treatment option is 
primarily used in higher risk patients, or those who fail primary therapies.  Current 
studies are underway testing novel azanucleosides including the use of new 
orally available compounds and combination trials.4,37  The third of the FDA 
approved drugs for MDS, is lenalidomide (LEN) (Revlimid®, Celgene Corporation, 
Summit, NJ).  LEN is approved for the treatment of red blood cell transfusion 
dependent patients with lower risk MDS and a chromosome 5q deletion.37  It is 
the first cytogenetically targeted therapy for MDS and will be discussed in greater 
detail in the next section of this manuscript. 
 The only potentially curative option currently for the treatment of MDS is 
allogeneic stem cell transplant (SCT).  This is often not an alternative for most 
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patients due to advanced age at disease diagnosis, co-morbidities, or lack of a 
compatible donor.4  Encouraging though, is the number of clinical trials either 
currently ongoing or in preliminary phases on novel targeted approaches to MDS.  
Some of these trials include inhibitors of transforming growth factor β (TGF-β), an 
inhibitory hematopoietic cytokine family; indoleamine 2,3 dioxygenease (IDO) 
inhibitors that abrogate expansion of Treg and myeloid derived suppressor cells 
(MDSC); multi-kinase inhibitors that block PI3K and Akt pathways; 
aminopeptidase inhibitors which are amino acid recycling regulators; and p53 
inhibition, particularly in LEN-resistant del(5q) MDS.37 
 
Immunomodulatory drugs (IMiDs®) 
 
Thalidomide.  Thalidomide is a glutamic acid analogue that was 
developed in Germany in 1954 (Figure 1).39,40  Thalidomide was approved in 
Europe as a sedative and anti-emetic later that decade under relatively lax 
regulatory scrutiny.39-41  Minimal animal models were tested, and similarities to 
other barbituates led governing boards to conclude its safety as a sedative.42  
Unfortunately, only a few years later in 1961, the drug was withdrawn from the 
market due to a tragically high number of cases of teratogenicity in newborn 
babies.39-41  It has been reported that more than 10,000 children from 46 
countries were affected worldwide.41,42  The majority of these cases involved limb 
malformations and congenital defects.41  Although the use of thalidomide as a 
sedative was encouraging, particularly due to the lack of toxicity recorded after  
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Figure 1.  Chemical structures of the IMiDs® thalidomide, lenalidomide, and 
pomalidomide 
 
overdose, the US FDA never approved the drug due to unanswered concerns 
regarding the drug’s safety, particularly with respect to neurotoxicity.39,41  
Interestingly, the European animal models used to test the efficacy and safety of 
thalidomide included only mice and rodents, however, it was later found that the 
teratogenicity of thalidomide is species specific and is restricted to chickens, 
rabbits, and humans.42  Even after several decades of research, the exact 
mechanisms of the teratogenicity remains unclear, although recent studies 
implicate inhibition of the cereblon E3-ubiquitin ligase complex.39,43  Cereblon will 
be discussed in further detail under the E3-ubiquitin ligase section of this 
manuscript.  
A diverse array of biological effects has been attributed to thalidomide.  
Some of these include anti-inflammatory activity, T and NK cell activation, and 
suppression of tumor necrosis factor α (TNFα) elaboration.41,42,44  These 
attributes, as well as others, led thalidomide to be termed the first 
immunomodulatory agent (IMiD®) in clinical use.  The anti-inflammatory effects 
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were found to be extraordinarily effective for erythema nodosum leprosum (ENL) 
and in 1998 the FDA approved the use of thalidomide in ENL patients.40,42,44  
Further studies with thalidomide revealed that it was also an effective anti-
angiogenic agent, a potentially useful attribute for treating cancer.40,42,44  In 2006, 
after several successful clinical trials, the FDA approved thalidomide for the 
treatment of multiple myeloma (MM).42,44  Although thalidomide is now approved 
for the treatment of several conditions, its use is heavily regulated.  In order to be 
prescribed in the US, patients, physicians, and pharmacists must all be 
registered in the System for Thalidomide Education and Prescription Safety 
(STEPS) program.  This program was created by Celgene (Summit, NJ) in order 
to limit both the marketing and the adverse effects of the compound observed 
worldwide.42,44   
 
Lenalidomde.  Studies of second generation IMiDs® were met with great 
optimism over the last decade.  These compounds are less toxic and more 
potent than their parent compound.44  Lenalidomide (LEN, RevlimidTM, CC-5013) 
is the most well studied second generation IMiD® and is structurally similar to 
thalidomide with only the addition of an amine group and loss of one carbonyl 
group (Figure 1).  LEN is up to 50,000 fold more potent than thalidomide as 
measured by inhibition of TNF-α, and more effectively suppresses elaboration of 
the pro-inflammatory cytokines IL-1β, IL-1, IL-6 and others, while promoting the 
production of anti-inflammatory cytokines such as IL-10.42,45,46  Additionally, LEN 
also enhances NK cell activity by promoting population expansion, stimulates 
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activation of T-cells by increased production of IL-2 and IFN-γ, and is 3 times 
more potent than thalidomide in its ability to inhibit angiogenic response.45,46  The 
modulation of the immune system by LEN is an intriguing therapeutic option for 
solid tumors.  Often, these tumors are able to evade the immune system by 
escaping activation of CD4+ cytotoxic T-cells and CD8+ helper T-cells.45  LEN 
activates both CD4+ and CD8+ cells, as well as hyper-sensitizes the T-cell 
receptor (TCR), and thus may be effective at limiting solid tumor burden.45   
Tested as both a single agent and in combination in a number of solid 
malignancies including melanoma, prostate, pancreatic, thyroid, brain, ovarian 
cancer, and others, efficacy in solid tumors is thus far disappointing.45  However, 
there are still more than 200 clinical trials ongoing and as the mechanisms of 
LEN are uncovered, it is likely that these findings may prove more positive.45
 Although, LEN’s activity in solid tumors has not been particularly 
encouraging, there is considerable efficacy in hematological malignancies.  In 
2005, combination treatments of LEN with the steroids prednisone or 
dexamethasone, with or without the addition of the proteasomal inhibitor, 
bortezomib, or in combination with the standard care chemotherapy, melphalan, 
in MM patients received much attention.40,46  These combination therapies were 
very successful, in fact, in the Phase II LEN-melphalan-prednisone trial, there 
was partial response or better in over 80% of elderly patients newly diagnosed 
with MM.40  Additionally, there was almost a 25% complete response rate.40  
These data were staggering considering the overall poor success of previous 
regimens.  In 2006, LEN was approved for the treatment of MM in patients with 
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one prior therapy (www.fda.gov).  Although these data are particularly hopeful, 
perhaps the most successful story of LEN is in the treatment of del(5q) MDS. 
 
Lenalidomide in MDS.  In 2005, a clinical study of 43 lower risk MDS 
patients, with either no response to Epo or limited suspected benefit was 
published by List et al. in the New England Journal of Medicine.6  In this study, 
56% of all patients responded with almost half achieving sustained transfusion 
independence.6  Perhaps the most intriguing aspect of this study, was the fact 
that 83% of the patients with a del(5q) abnormality responded with normalization 
of hemaglobin.6  These numbers were shocking as previous therapies for MDS, 
particularly del(5q) MDS, had been disappointing.  In a follow up study of 148 
del(5q) MDS patients, 76% showed reduced need for transfusions, while 67% 
became transfusion independent.1  Transfusion independence was accompanied 
by cytogenetic improvement suggesting cytotoxicity to the del(5q) clone.1  These 
studies prompted the FDA to approve the treatment of LEN in lower risk del(5q) 
MDS patients in 2005.46  As exciting as these results were, and continue to be, 
the exact mechanisms and direct targets of LEN were, and are, still not clear.  
We do, however, know that LEN has specific mechanisms of action that can 
account for the biological effects of LEN in non-del(5q) and del(5q) MDS 
independently.    
 
Lenalidomide in non-del(5q) MDS.  In non-del(5q) MDS, LEN restores 
hematopoiesis by expanding the erythroid progenitor population, as well as 
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overcoming the diminished Epo induced STAT5 activation in MDS patients 
without observed cytotoxicity to the MDS clone.47-49  Although MDS patients have 
either comparable or elevated levels of endogenous Epo with no defects in ligand 
binding to receptor, activation of STAT5 through the Epo receptor (EpoR) is 
diminished compared to normal progenitors.49  LEN augments Epo induced 
STAT5 activation and prolongs the duration of activation compared to Epo 
stimulation alone, promoting erythroid expansion.  Although LEN is able to 
rescue ineffective hematopoiesis in non-del(5q) MDS patients, the transfusion 
independence response rate for this subset of patients is only about 25%.6  In 
2008, Ebert et al. published a gene signature which was predictive for LEN 
response in non-del(5q) MDS and found that there was a decrease in a set of 
erythroid differentiation genes in patients that responded to LEN.50  Upon LEN 
treatment, these genes were upregulated correcting the defective erythroid 
differentiation patterns.50  Although this gene signature may provide a good 
biomarker to identify the non-del(5q) MDS patients that may respond to LEN, 
clinical use of this data has yet to occur.  Furthermore, underexpression of these 
lineage specific genes may reflect the impairment in EpoR signaling.  The 
precise mechanism of action of how erythroid expansion, or induction of erythroid 
differentiation genes occurs, is not yet fully understood and is addressed in this 
study. 
 
Lenalidomide in del(5q) MDS.  Response rates in del(5q) MDS are much 
more promising but seem to occur via mechanisms that are distinct from that in 
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non-del(5q) MDS.  There is approximately a 75% transfusion response rate in 
lower risk non-del(5q) patients treated with LEN.1  These astonishing findings led 
to LEN becoming the first targeted therapy for lower risk del(5q) MDS patients, 
approved by the FDA in 2005.  It was also observed that responding patients 
commonly showed loss of the del(5q) clone after treatment, suggesting direct 
cytotoxicity to this clone.1  Selective cytotoxicity of the del(5q) clone was 
confirmed by our laboratory with collaborators in 2009.51  We determined that 
clonal sensitivity was a result of LEN’s inhibitory effect on two haplodeficient  
phosphatases, CDC25c and PP2Acα.51  Both genes are located in the del(5q) 
CDR, and when non-del(5q) MDS primary samples were lentivirally infected with 
shRNA for either CDC25c and/or PP2A, the cells underwent an apoptotic 
response after LEN exposure similar to del(5q) cells.51  We also found the LEN 
inhibited the enzymatic activity of CDC25c and PP2Acα, by direct and indirect 
actions, respectively.51  These phosphatases are key regulators of the cell cycle, 
and in our experiments, LEN induced a G2-M cell cycle arrest in the del(5q) 
cells.51  These results were consistent with a previous study showing selective 
cytotoxicity of the del(5q) clone to LEN.  In that study, the authors proposed the 
selective cytotoxicity may involve upregulation of the CDR encoded tumor 
suppressor gene, SPARC.52   Upregulation of SPARC by LEN however was not 
restricted to del(5q) clones, and therefore appears to be universal drug effect.52  
In summary, LEN enhances erythropoiesis in both non-del(5q) and del(5q) MDS, 
albeit by two different mechanisms.  Erythroid differentiation and expansion is 
observed in non-del(5q) patients, whereas, selective cytotoxicity is observed in 
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del(5q) patients.  Additional findings from our laboratory on the mechanisms of 
LEN in del(5q) patients will be discussed E3 ubiquitin ligase section of this 
manuscript.   
 
Pomalidomide.  Pomalidomide (CC-4047, Actimid, Pomalyst, Celgene 
Corporation, Summit, NJ) is a third generation immunomodulatory agent, that 
may be even more potent than LEN.  Similar to LEN and thalidomide, 
pomalidomide suppresses TNF-α, stimulates T-cells, expands NK cell numbers, 
and has anti-angiogenic properties.  Currently there are several clinical trials 
investigating the effects of pomalidomide, particularly in MM.40  The first Phase I 
study of pomalidomide in multiple myeloma, showed a reduction in paraprotein in 
67% of patients and a complete response in 10% of patients.40  Subsequently, 
several Phase II studies were performed testing the efficacy of dexamethasone 
and pomalidomide in refractory or relapsed MM.  Results were very encouraging 
with responses observed in more than 60% of patients.40,53  Perhaps of most 
importance, is the effectiveness of pomalidomide/dexamethasone in thalidomide, 
LEN, and bortezomib refractory multiple myeloma patients.40,53  In one study, 
pomalidomide/dexamethasone treatment was effective in 40% (8/20) of LEN-
refractory patients, 37% (6/16) of thalidomide refractory patients, and 60% (6/10) 
of bortezomib refractory patients as well as 60% (3/5) bortezomib and LEN 
refractory patients.53  These surprising results, in combination with several other 
clinical studies, led to the FDA accelerated approval of pomalidomide in 
refractory myeloma patients on Feb 8, 2013 (www.fda.gov).  Currently, 
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pomalidomide is also being testing in myeloproliferative neoplasms and in some 
solid tumors with efficacy and reporting yet to be concluded. 
 
Ribosomopathies   
 
Overview.  In 1999, mutations in ribosomal protein S19 gene (RPS19) 
were found to be associated with the disease pathogenesis of Diamond-Blackfan 
anemia (DBA).54  Although it may have not been known at the time, this finding 
would become the premise for the characterization of a spectrum of disorders 
now known as ribosomopathies.  Several congenital hypoplastic anemias caused 
by mutations of genes or somatic deletion of genes encoding proteins involved in 
ribosome biogenesis as in del(5q) MDS, can be broadly categorized as 
ribosomopathies.55  In order to understand these diseases, a brief review of 
ribosome biogenesis is warranted (Figure 2).  The creation of ribosomes is an 
energy intensive process that is highly regulated and is vital to both cell growth 
and cell division.56  This process involves hundreds of individual steps, 4 
ribosomal RNAs (rRNA), at least 80 different ribosomal proteins (RPs), over 150 
associated proteins, and an estimated 70 small nucleolar RNAs, as well as the 
coordinated effort of RNAses.57,58  Ribosomal DNA is transcribed into a 45S 
precursor by RNA polymerase (pol) I.56  This precursor will be spliced into 28S, 
18S, and 5.8S rRNAs.56,58  At the same time, RNA pol III is transcribing an 
additional 5S subunit.  In association with RPs transcribed by RNA pol II, and 
other associated proteins, 60S and 40S ribosomal subunits will be formed from 
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these precursors, and will be exported to the cytoplasm where they join to form 
the mature 80S ribosome (Figure 2).56,58  Ultimately, it is the responsibility of the 
ribosome to translate mRNA and manufacture all proteins necessary for the life 
of the cell.  These process are highly regulated by a stoichiometric relationship 
between precursors and mature subunits, and deregulation can have severe 
cellular consequences.56 
The finding of RPS19 mutations in DBA provided the foundation for the 
study of a number of disorders now known as ribosomopathies.  Interestingly, the 
majority of these disorders involve bone marrow failure associated with 
hypoplastic or non-regenerative anemia.  DBA is a heterogeneous disorder 
characterized by anemia, erythroid failure, congenital abnormalities, and an 
increased risk for leukemic transformation.54,56,59  DBA is usually detected early in 
life (within the first year) and is a classic bone marrow failure syndrome with 
ineffective hematopoiesis and increased apoptosis of progenitors in the bone 
marrow compartment.56,59  Mutations in RPS19 occur in approximately 25% of all 
DBA patients, and since the original publications, mutations in four other RP 
genes have been identified accounting for up to 50% of mutations detected DBA 
patients.58,59  RPS19 is one of the RPs involved in the creation of the 40S subunit 
from the 18S subunit, and DBA patients harboring either mutations or 
haplodeficiency for this gene have decreased levels of the 40S subunit.56  
However, the exact mechanisms by which RPS19 causes a defect in 40S 
assembly is yet to be clearly defined.56 
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Figure 2.  Overview of ribosome biogenesis and ribosomopathy.  Ribosome 
biogenesis and suspected locations of altered biogenesis in ribosomopathies.  
Some of the suspected genes involved are provided in italics. (DC) dyskeratosis 
congenital, (CHH) cartilage-hair hypoplasia, (TCS) Treacher-Collins syndrome, 
(SDS) Shwachman-Diamond syndrome, (DBA) Diamond-Blackfan anemia. 
 
 A second bone marrow failure syndrome caused by defects in ribosome 
biogenesis is Shwachman-Diamond syndrome (SDS).  Nearly all SDS patients 
have severe neutropenia and anemia, with pancytopenia is observed in up to 
65% of patients.56,57  In SDS, mutations in the SBDS gene are suspected to be 
involved in disease pathogenesis.  SBDS is also suspected to be involved in 40S 
maturation, although the mechanism by which this occurs in humans has yet to 
be determined.57  In X-linked dyskeratosis congenital (DC), mutations in DKC1, a 
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gene thought to be involved in the processing and modifications of the 45S 
subunit, are suspected to be linked to disease pathogenesis.56,57  Pancytopenia 
and severe aplastic anemia is observed in the majority of X-linked DC 
patients.56,57  Cartilage hair hypoplasia (CHH), along with several other clinical 
features, presents with hypoplastic anemia and is suspected to be caused by 
mutations in the RMRP gene, which is important for the RNAse complex and 
splicing of the 45S subunit.56,57  Treacher-Collins syndrome (TCS), characterized 
by craniofacial abnormalities similar to those observed in DBA, is thought to be 
caused by mutations in TOCF1.  The TOCF1 gene encodes Treacle which 
effects ribosome DNA transcription by binding an RNA pol I transcription 
factor.57,58  Collectively, all these syndromes represent classical ribosomopathies 
and bone marrow failure, suggesting a critical role for ribosome biogenesis in the 
bone marrow compartment. 
 
The 5q- syndrome as a ribosomopathy.  In 2008, Ebert et al. 
demonstrated that haploinsufficiency for RPS14 was responsible for the 
hypoplastic anemia of the 5q- syndrome.23  Although, haploinsufficiency for 
CDC25c and PP2Acα has been demonstrated to be responsible for LEN 
sensitivity,51 these RPS14 data were the first to describe a pathway singularly 
responsible for the pathogenesis of anemia in MDS.  The CDR of del(5q) has 
been extensively studied, and most research sought to find a tumor suppressor 
gene responsible for disease development.  These studies were all unsuccessful 
at identifying such a gene.20,22  Since no mutations or biallelic deletions have 
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ever been identified, Ebert et al. hypothesized that haploinsufficiency may be the 
cause of disease phenotype.23  In an effort to test this hypothesis, the 
investigators generated a panel of shRNAs targeting the 41 genes contained 
within the CDR.23  Each gene was knocked down by approximately 50% in order 
to mimic the allelic haploinsufficiency.  Partial loss of only RPS14 mimicked a 5q- 
phenotype, which was resolved in RPS14 add back experiments.23  RPS14 
knockdown caused proliferative arrest and loss of differentiation of mature 
erythroid cells, and ultimately is the cause of hypoplastic anemia in the 5q- 
syndrome phenotype.23  Although the exact functions of RPS14 are unknown, 
knockdown resulted in a decrease in 18S rRNA suggesting aberrant splicing of 
precursor RNAs.23  These data were confirmed in a mouse model, where 
deletion of all genes in the human CDR including RPS14 recapitulated the 
disease.21  In summary, RPS14 haplodeficiency is implicated in del(5q) MDS 
pathogenesis, and provides further insight into disease biology. 
  
Phenotypical differences in ribosomopathies.  These syndromes all 
represent a new class of syndromes known as ribosomopathies, and interestingly, 
most are also bone marrow failure syndromes.  For the first time, a group of 
diseases is recognized by the failure of a cell to effectively produce mature 
functioning ribosomes, whether it be due to mutation or haplosufficiency.  The 
question arises, what causes the distinct phenotypes in each of these diseases, 
and why do they seem to be specific or preferential to the bone marrow?  The 
answer to this is yet to be determined; however, proposed models exist and are 
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currently being investigated.  According to a review by Ganapathi and 
Shimamura, these models are generally as follows, 1) highly proliferative cells 
such as erythroid progenitors and/or hematopoietic stem cells are particularly 
sensitive to ribosome biogenesis ineffectiveness, 2) specific mRNAs particular to 
the bone marrow may be selectively effected, 3) certain tissues may be 
selectively sensitive to decreased ribosome biogenesis, 4) cells with high output 
of RPs may be selectively sensitive to an accumulation of free RPs in the cell, 
and 5) increased cell cycle arrest and/or apoptosis may be particularly 
detrimental to hematopoietic stem cells.56  Although, none of these models have 
yet to be proven, there is one common theme that may serve to link them, and 
describe how aberrations in ribosome biogenesis pathway may cause a number 
of phenotypically diverse syndromes.  This link is an accumulation of the tumor 
suppressor, p53. 
  
Stabilization of P53.  The p53 tumor suppressor has a number of cell 
regulatory functions including cell cycle and apoptosis.  The E3-ubiquitin ligase, 
MDM2, is the principal negative regulator of p53 and targets p53 for proteasomal 
degradation.  Free or unbound RPs are able to bind to MDM2 rendering it unable 
to bind to, and ubiquitinate p53, thus leading to the stabilization of p53.60  In 
ribosomopathies, disruption of ribosome biogenesis results in nucleolar stress 
and the release of free, unbound RPs.  These RPs bind to and promote the 
degradation of MDM2, thereby stabilizing p53 (Figure 3).60,61  Haploinsufficiency 
of RPS14 and RPS19 resulted in erythroid specific accumulation of p53 and 
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consequent cell cycle arrest.62  This phenomenon likely accounts for the lack of 
mature erythroid cells in both the 5q- syndrome and DBA.62  Interestingly, 
inhibition of p53 restored hematopoiesis, while activation by Nutlin-3 also 
impaired erythropoiesis.62  Similarly, in Barlow’s et al. syntenic mouse model, 
phenotypically similar to the 5q- syndrome, inactivation of p53 was sufficient to 
rescue the hematologic phenotype in these animals.21  These findings suggest 
that lineage specific stabilization of p53 due to nucleolar stress and excessive 
unbound RPs, may account for the phenotypic heterogeneity of bone marrow 
failure syndromes and/or ribosomopathies and may be a potential therapeutic 
target of these syndromes. 
 
Figure 3.  Stabilization of p53 after ribosomal or nucleolar stress observed in 
ribosomopathies.  Without nucleolar stress, the 40S and 60S with ribosomal 
proteins (RP) come together to form mature, functioning ribosomes, and MDM2 
is free to bind and ubiquitinate p53.  However, under nucleolar stress conditions, 
unbound RPs are able to bind to MDM2 preventing its binding to p53 resulting in 
stabilization of p53. (rRNA) ribosomal RNA. 
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Hematopoiesis 
 
Overview.  Hematopoiesis, or the process of mature blood cell production, 
is a highly regulated process that in addition to producing the cells needed to 
maintain vital functions, is also regulated in times of infection or bleeding and is 
often deregulated in hematological malignancies.  Hematopoiesis occurs through 
an intricate coordination between cytokines and transcription factors.63-65  
Although a full description of the complexity of hematopoiesis may very well 
encompass this entire manuscript, a brief review is warranted for the following 
study.  Briefly, hematopoietic stem cells (HSC), capable of both self-renewal and 
commitment to all mature blood lineages, differentiate into lineage committed  
progenitors which mature into precursors ultimately resulting in blood cells.63-65  
Upon particular cytokine stimulation, multipotent HSC will differentiate into either 
common lymphoid (CLP) or common myeloid progenitors (CMP).63-65  CLPs will 
mature into T-cell and natural killer (NK) cell progenitors, which turn to mature T- 
and NK cells.63-65  The CLP may also differentiate into a B-cell precursor, and 
ultimately mature B-cells.63-65  The CMP will differentiate into mature erythrocytes, 
megakaryocytes and platelets, neutrophils, macrophages, basophils, eosinophils, 
and mast cells.63-65  The progenitor and differentiating status of primary samples 
can be identified in vitro using colony forming capacity (CFA) assays.  In CFAs, 
primary cells are plated in a semi-solid medium supplemented with appropriate 
cytokines, and after 14 days, colony types, or progenitor potential, may be 
determined based on the different morphological characteristics of the 
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colonies.66,67  Colony forming units-granulocyte, erythroid, macrophage, 
megakaryocyte (CFU-GEMM) is a mixed lineage progenitor that differentiates 
into CFU-granulocyte, macrophage progenitors (CFU-GM), as well as the burst 
forming unit-erythroid (BFU-E).66,67  BFU-E are the most primitive of the erythroid 
progenitors and are dependent on the growth factor, erythropoietin (Epo), for 
maturation.66,67  BFU-E will differentiate into CFU-E which are also dependent on 
Epo for maturation, and will eventually complete terminal maturation into 
erythrocytes.66,67  The maturation and proliferation of the erythroid lineage is also 
dependent on the transcription factor, GATA-1.63  A decrease in GATA-1 
expression in a mouse model resulted in a decrease in erythroid precursors.65  A 
thorough review of the erythropoietin receptor signaling pathway and the 
transcription factors involved in erythropoiesis will be provided under 
Erythropoietin Receptor Signaling.  An overview of hematopoietic differentiation 
is represented in Figure 4.   
 
Hematopoiesis in MDS.  A hallmark of all bone marrow failure 
syndromes is ineffective hematopoiesis.  Erythropoiesis is often highly disrupted 
in MDS despite comparative levels of the EpoR, and similar or elevated levels of 
endogenous Epo in MDS patients compared to normal controls.49  In the case of 
del(5q) MDS, defective erythropoiesis is caused by allelic haploinsufficiency for 
the RPS14 gene product and consequent lineage specific stabilization of p53.23,62  
Alternatively, in non-del(5q) MDS, there are several factors contributing to  
ineffective hematopoiesis and erythropoiesis.68  Kitagawa et al. demonstrated  
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Figure 4.  Hematopoiesis.  The hematopoietic stem cell (HSC) may differentiate 
into either common lymphoid or common myeloid progenitors (CLP or CMP).  
The CLP produces all mature T-, B-, and NK cells, while the CMP will 
differentiate into all other blood cell types.  The colony forming unit-granulocyte, 
erythroid, macrophage, megakaryocyte (CFU-GEMM), matures into CFU-
granulocyte, macrophage progenitors (CFU-GM) that will mature to neutrophils 
and macrophages, as well as the burst forming unit-erythorid (BFU-E), and 
colony forming unit-erythroid (CFU-E), that will eventually evolve into mature 
ertyhrocytes. 
 
that bone marrow macrophages from MDS patients express higher levels of 
tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ), inhibitory 
hematopoietic cytokines, compared to normal primary cells.69  An increase in 
these cytokines suppresses maturation and differentiation in normal 
hematopoietic progenitors, and is implicated in the observed cytopenias in 
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MDS.69  These inflammatory cytokines also induce surface membrane 
expression of the death receptor, Fas, and its ligand, Fas-L, in erythroids 
enabling lineage specific apoptosis.70  Alternatively, defective hematopoiesis in 
MDS may also relate to epigenetic silencing of genes critical to cell growth and 
maturation.68,71-73  Aberrant promoter methylation of genes involved in cell cycle 
regulation, differentiation, and apoptosis.68,71-73  Hypermethylation of key 
regulatory genes leading to gene silencing and decreased expression of proteins 
such as survivin, CHK2, and WT1, lowers cellular threshold for apoptosis in early 
progenitors thereby accelerating the loss of maturing erythroid cells.68,71  Wei et 
al. used a CHIP-Seq analysis in CD34+ cells isolated from MDS patients to 
identify hypermethylation involving 36 genes, the majority of which were involved 
in NF-κB activation and innate immunity.72  Del Rey and colleagues showed that 
hypermethylation silencing key genes involved in cell survival, i.e. Bcl2 and 
ETS.73  Del Rey et al. also showed aberrant innate immune response due to 
hypermethylation and silencing of IL27RA and DICER1, regulators of microRNA 
biogenesis.73  Additionally, effectors of DNA methylation such as DNA 
methyltransferase (DNMT)-3a and 3b, were found to be increased in higher risk 
MDS patients compared to lower risk patients and normal controls, providing 
further evidence that gene methylation and epigenetic gene silencing in general 
may be important in the pathogenesis of the disease.71  These findings provided 
the basis for 2 of the 3 of the drugs currently approved by the FDA for MDS, 5-
azacitidine (azacitidine, Vidaza®) and 5-aza-2’-deoxycitidine (decitabine, 
Dacogen®).74,75  These azanucleosides were shown to have in vivo 
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demethylating properties and improve hematopoiesis as evidenced by 
hematologic improvement in 30-50% of MDS patients.74,75   
In the following investigations, focus will be placed on ineffective 
erythropoiesis in MDS, particularly as it relates to Epo initiated signal response in 
MDS progenitors. 
 
Erythropoietin Receptor Signaling 
 
Erythropoietin.  Erythropoietin (Epo) is a 34kD glycoprotein hormone that 
is responsible for red blood cell (RBC) survival, proliferation, and 
differentiation.70,76-78  The Epo gene was cloned in 1985 following delineation of 
gene location and subsequent functional analysis.70,76-79  Epo is primarily 
produced in the kidney with about 20% production from the liver in adults.77,79  
The Epo gene is transcriptionally regulated and is activated in times of hypoxia or 
bleeding, in addition to balancing the basal level of mature erythrocyte mass.11  
Recombinant human Epo (rhEpo) has been used to treat the anemia in 
conditions of endogenous hormone production such as renal failure and in 
acquired immunodeficiency syndrome (AIDS), as well as in patients with a variety 
of causes of anemia such as that related to chemotherapy, and in patients with 
MDS.70,76,77,79  In each of these cases, treatment with rhEpo induces the 
production of mature RBCs, alleviating anemia in a significant proportion of 
patients.  Interestingly, due to the increase in RBC production and tissue oxygen 
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delivery, Epo has been exploited as a doping agent in endurance related sports, 
and has been banned in most countries by sporting governing agencies.79 
 
Erythropoietin receptor.  All biological effects of Epo occur after binding 
of the cytokine to the cognate dimerized receptor, EpoR.  The primary cell 
lineage expressing EpoR is erythroid progenitors, although its expression has 
been identified on a number of cell types including endothelial cells, mammary, 
brain, kidney and cardiac muscle cells, and may be found on a number of non-
hematologic tumor types.80-82  The EpoR is a Type I cytokine receptor with no 
intrinsic kinase activity.  Although it is responsible for all Epo induced cell 
stimulation, there are predicted to be less than 1000 receptors per cell.70,79,83,84  
This finding suggests that the regulation of its production, and cell surface 
expression, is a highly regulated process. 
 
EpoR maturation, transport, and turnover.  Since the cloning of Epo 
and subsequently its receptor, the maturation, transport, and turnover of the 
receptor has been extensively investigated.  Cell surface expression of the EpoR 
is dependent on the Janus Kinase 2 (Jak2) protein.70  EpoR is initially contained 
in the endoplasmic reticulum (ER) where only about 20% will mature and be 
transported to the Golgi apparatus.83  Of the Golgi EpoR, only a small proportion 
will fully mature and be transported to and expressed on the cell surface.83  This 
demonstrates the highly regulated process of cellular EpoR expression and 
assures that an excess of receptor is readily available under conditions of 
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hypoxia and/or bleeding for the production of mature RBCs.  Jak2 binds to the 
EpoR in the ER and with assistance of an EndoH oligosaccharide, is transported 
to the Golgi apparatus as a receptor complex.83  Full maturation of the receptor 
and transport to the cell surface occurs after heavy glycosylation.83  Upon 
receptor stimulation by its ligand, EpoR is ubiquitinated at the cell surface and is 
quickly internalized into the cytoplasm.  EpoR ubiquitination targets the protein 
for proteasomal degradation which prevents further signal transduction by 
removing the phosphorylated tyrosine residues on the cytoplasmic tail, and 
allows parts of the receptor to be recycled.84-86  Two E3 ubiquitin ligases have 
been implicated in the degradation of EpoR and Type I Jak2-associated cytokine 
receptors, β-Trcp and RNF41.85,87  E3 ubiquitin ligases and their functions as 
they relate to these investigations will be discussed in the E3 Ubiquitin Ligase 
section. 
 
EpoR signaling.  Structure of the EpoR is similar to other Type I cytokine 
receptors including a cytoplasmic, transmembrane, and extracellular domain and 
no intrinsic kinase activity.78,88,89  The signaling cascade triggered by EpoR 
stimulation has been extensively studied, and a generalized schematic is 
summarized in Figure 4.  Upon Epo binding to its receptor, a conformational 
change of the receptor causes homodimerization.79,88  Dimerization causes the 
phosphorylation and activation of the constitutively associated Jak2 
protein.70,78,79,88,90  Mouse embryos without Jak2 lack RBCs.78  Jak2 
autophosphorylates itself but also phosphorylates 8 tyrosine residues on the  
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Figure 5.  Schematic of EpoR Signaling.  Erythropoietin binds EpoR which 
homodimerizes and triggers auto-phosphorylation of Jak2.  Jak2 phosphorylates 
tyrosine residues on the cytoplasmic tail of EpoR as well as STAT5, the latter of 
which then dimerizes and translocates into the nucleus where it binds DNA and 
turns on pro-survival, proliferation, and differentiation genes.  The 
transmembrane tyrosine phosphatase CD45 is a negative regulator of the 
pathway, which dephosphorylates tyrosine residues on Jak2, lyn kinase, and the 
EpoR cytoplasmic tail.  
  
cytoplasmic tail of EpoR.78,79,89-91  These phosphorylated residues act as docking 
sites for a number of other signaling intermediates via their SH2 homology 
domains.70,78   
Although a number of signaling pathways are activated by Epo stimulation, 
perhaps the most extensively studied pathway involves the Signal Transducer 
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and Activator of Transcription (STAT)5.70,78,88,92  Jak2 phosphorylates STAT5 
which initiates dimerization of the protein and translocation to the nucleus where 
it binds DNA and initiates the transcription of anti-apoptotic genes such as Bcl-X, 
a Bcl-2 family member protein.78,79,88,89,92  STAT5 deficient mouse embryos are 
severely anemic.78  In addition to STAT5, activation of GATA-1 transcription 
factor is necessary for erythroid cell development based on studies of null mouse 
models.49,93  GATA-1 regulates a number of genes involved in erythroid 
differentiation including EpoR and Sp1 genes as well as inhibiting apoptosis in 
erythroid precursors.49,93  GATA-1 was shown to be activated through the 
phosphotidyl-3 kinase (PI3K) /Akt pathway.94  Phosphorylation of GATA-1 by 
PI3K is necessary for Epo induced growth of erythroid progenitors.94  The PI3K 
pathway is activated in part through receptor binding of Grb2 and Vav. 70,78,79,89  
Vav and Grb2 additionally activate Ras and Rac, members of the Rho GTPase 
family of proteins78,89,95-97  The GTPases are molecular switches that cycle 
between active GTP-bound and inactive GDP-bound states and are involved in 
the regulation of cellular component trafficking and cytoskeletal changes.96,97  
GTPases will be discussed in more detail later.  Lyn kinase is also activated and 
associated with the receptor at the cell surface.70,89  Lyn kinase phosphorylates 
both the EpoR and Stat5 to cooperate in the potentiation of Epo signaling.89  The 
mitogen-activated protein kinase (MAPK) pathway is similarly activated after Epo 
stimulation, and has been shown to be additionally responsible for the activation 
of Rho kinase.70,79,96  Regardless of the pathway involved, EpoR signaling 
induced by cytokine stimulation is essential for not only basal RBC maintenance 
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and production, but also in anemia caused by erythropoietic insult or hypoxia.   
Therefore aberrations of this pathway are critical limiting factors in the 
pathogenesis of anemia in select hematologic disease pathogeneses, and 
provide possible therapeutic targets. 
 
Negative regulation of EpoR signaling.  Negative regulation of the 
EpoR pathway is primarily coordinated through negative feedback loops.92  This 
regulation is accomplished by a number of phosphatases and a family of proteins 
known as the suppressors of cytokine signaling (SOCS).  The SOCS proteins 
bind Jak2 inactivating it, block STAT5 binding sites on the receptor, and 
ubiquitinates signaling proteins, all of which halt Epo induced signaling.92  The 
major phosphatases involved in the negative regulation of this pathway include 
hematopoietic cell phosphatase (HCP, SHP-1 or PTP1C) and CD45.70,78,88,92  
SHP-1 dephosphorylates Jak2 causing its inactivation and halting downstream 
signaling.70,78,88  The transmembrane phosphatase, CD45, is essential for both T-
cell and B-cell regulation, as well as EpoR signaling.98  CD45 dephosphorylates a 
number of proteins including Jak2.98  Lastly, receptor recycling and turnover also 
regulates Epo induced signaling.  After ligand binds the receptor, it is 
immediately ubiquitinated and either degraded or recycled back into the cell.86 
 
EpoR signaling in MDS.  Patients with MDS have comparable levels of 
both endogenous Epo and normal cellular membrane density of EpoR, however, 
clear functional inadequacies are evident compared to normal controls.49  Given 
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that there is no identified loss of ligand binding to the receptor, impaired 
activation of STAT5 must relate to a deficiency in the signaling pathway.49  
Unfortunately, the exact mechanism underlying signal impairment remains 
elusive.  Hoesfloot et al. reported that there is a marked decrease in Epo induced 
DNA transcription and binding of GATA-1 in MDS patients compared to normal 
controls.49  A loss of GATA-1 transcriptional activity was followed by decreased 
maturation in response to Epo, and loss of erythroid or Epo responsive cells.49  It 
was also found that STAT5 activation after Epo stimulation was either 
undetectable or at very low levels in MDS progenitors.49  The diminished STAT5 
activation coincides with a decrease in erythroid colony-forming capacity and Epo 
induced DNA synthesis.49  Furthermore, the decrease in STAT5 activation was 
not due to low numbers of erythroid cells, suggesting that the site of dysfunction 
is an early event likely preceding activation of STAT5.49  Furthermore, it suggests 
that ineffective erythropoiesis in MDS may be caused by a defect in the signaling 
cascade.  Since Hoesfloot et al. published their reports in 1997, the mechanism 
of decreased signaling has still yet to be identified.  In this manuscript, we 
propose that impairment in lipid raft signaling platforms are responsible for 
decreased STAT5 activation and provide a novel finding on the disease biology 
of MDS and possible therapeutic strategies. 
 
Lipid Rafts 
 
Identification and composition.  The plasma membrane is a fluid 
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 phospholipid bilayer.  Within this fluid membrane structure, discrete entities 
composed of tightly packed sphingolipids and cholesterol ‘float’ freely.  These 
platforms are termed lipid, or membrane, rafts.99,100  The rigidity and relatively 
ordered state of lipid rafts are a consequence of the saturated acyl chains on the 
sphingolipids in contrast to the unsaturated fatty acyl chains of the 
phospholipids.101  High levels of sphingolipids and cholesterol in the apical 
domain of polarized epithelial cells was the first evidence of the existence of lipid 
rafts.100,102-104  Since these initial findings almost 20 years ago, accumulating 
evidence reveals that rafts are formed through a lateral association of 
sphingolipids that are held together by their hydrocarbon chains and tightly 
associated cholesterol molecules.102,105  Rafts are associated with 
glycosylphosphatidylinositol (GPI)-anchored proteins, cytokine receptors, kinases, 
and GTPases that mediate intracellular signaling in response to varied external 
stimuli (Figure 6).102,105  The sterol composition of the lipid rafts renders them 
relatively insoluble to detergent lysis at 4°C and therefore they are also 
sometimes referred to as detergent resistant membranes (DRM) or detergent-
insoluable, glycolipid-enriched complexes (DIGs).102,106  There is reported to be 
10x more cholesterol in the raft fractions compared to non-raft fractions, however, 
how much of the plasma membrane is actually accounted for by lipid rafts 
remains controversial.106  Studies of raft size vary greatly but reports suggest that 
they may range anywhere from 10-200nm.101,102  Although exact sizes of rafts 
are disputed, it is agreed that they are relatively small under steady state 
conditions, but that they increase in size due to aggregation upon external stimuli, 
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Figure 6.  Lipid Rafts.  Lipid rafts are composed of tightly packed sphingolipids 
and cholesterol forming platforms that contain GPI anchored proteins, cytokine 
receptors, kinases, and GTPases that mediate cell signaling   
 
a process which is necessary to mediate downstream signaling pathways.102,105 
 
Raft formation.  The process of raft assembly and aggregation is 
accomplished through intricate coordination with the actin cytoskeleton.101  The 
actin cytoskeleton is a dynamic assembly of subunits that changes in response to 
external stimulation.107  Interaction between the actin cytoskeleton and lipid rafts 
is suspected to be involved in protein trafficking as well as translocation of raft 
subunits from the Golgi to the plasma membrane.101  Cholesterol is produced in 
the ER, however, sphingolipids are produced in the Golgi.102  Raft assembly is 
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initiated in the ER, but after component glycosylation, moves to the Golgi where 
manufacturing occurs before translocation to the membrane.102,107,108  
Sphingoliphid and cholesterol stores are maintained at the trans Golgi network 
and are available under appropriate conditions to promote rapid coalescence and 
recruitment of signaling molecules.107  Each of these processes is mediated 
through the actin cytoskeleton.102,107,108  Although actin itself does not interact 
with the lipid rafts, these proteins act as a scaffolding between the raft 
constituents and cytoplasmic proteins, and also serves as tracks to guide protein 
transport.101  The aggregation of rafts is dependent upon reorganization of 
filamentous (F)-actin.101,107  These rearrangements are coordinated in part 
through the dedicator of cytokinesis 2 (DOCK2) and Rac GTPases.101  RhoA and 
Rho associated-coil-coil-containing protein kinase (ROCK) are also particularly 
important for this process.101  Rac GTPases will be discussed in greater detail 
shortly.  The actin cytoskeleton is not only dynamic, but bidirectional, therefore 
the same pathways leading to the formation of the rafts and shuttling to the 
membrane, are also used in raft recycling and negative feedback loops.107  
Endocytosis of rafts may lead to recycling back to the plasma membrane, 
recycling back to the Golgi, or dissociation.109 
 
Functions.  Since their identification in polarized epithelial cells, lipid rafts 
have since been implicated in a number of cellular processes.  For example, rafts 
are the point of entry for a number of infectious pathogens.  Some pathogens 
known to be dependent on rafts for cell invasion include the malaria parasite, 
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Plasmodium falciparum, the influenza virus, and HIV-1.102,105,110-112  Disruption of 
lipid rafts inhibited entry of each of these pathogens indicating a critical role of 
the rafts in cell penetration and infection.102,105,110-112  Other raft functions can be 
exemplified by showing the diversity of proteins that are functionally dependent 
on membrane rafts.  Both the B-cell receptor (BCR) with CD20 and CD19/CD21 
complexes, and the T-cell receptor (TCR) are present in raft fractions.101,113  The 
dependence of T-cell activation on lipid rafts has been extensively studied and 
will be discussed in the next section.  There are also a number of cytokine 
receptors known to reside in rafts, including the vascular endothelial growth 
factor (VEGF), granulocyte-macrophage colony stimulating factor (GM-CSF), 
epidermal growth factor (EGFR), and insulin-like growth factor receptor 
(IGFR).114  The presence of these cytokine receptors (and others) in lipid rafts 
signifies the importance of rafts in cytokine signaling.  The FcǫRI receptor, 
important for IgE signaling resides in lipid rafts suggesting a role in allergic 
reactions as well as parasite immunity.113  The death receptor complex, 
Fas/CD95, also resides in lipid rafts implicating a role of in apoptosis.115  The 
ATP-binding cassette transporters (ATP transporters) including P-glycoprotein 
(Pgp) and Multidrug resistance-associated protein 1 (MRP-1) are located in rafts, 
suggesting a role in multidrug resistance.116  G-protein coupled receptors 
(GPCRs), such as the dopamine receptors, are constitutively associated with 
lipid rafts implicating an importance for neuronal signaling.116-119   Ferroportin, the 
protein responsible for iron export in macrophages, is dependent on lipid rafts.120  
Integrins involved in cell to cell contact, migration, and metastasis also reside in 
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the rafts.101  Rafts are also important for endocytosis, a process by which 
receptors are internalized into the cell after ligation.102  Some of the most highly 
raft associated proteins are the Src family kinases, such as Lyn kinase.102,105,113  
Lyn kinase acts as a mediator between raft domains and signaling effectors 
further supporting the important role of rafts in cell signaling.  The presence and 
functional dependence of these proteins on rafts localization demonstrates the 
diversity and magnitude of cellular processes associated with these membrane 
microdomains. 
 
T-cell signaling.  The role of lipid rafts in signaling has been most 
extensively studied in T-cell activation.121  Upon stimulation, T-cell receptors 
(TCR) coalesce in the lipid rafts, compartmentalizing with associated signaling 
proteins.109,122  TCR is associated with GPI-anchored proteins and the clustering 
of lipid rafts marks localization of the immune synapse.123,124  This clustering 
occurs via the raft constituent, ezrin, an ERM (ezrin, radixin, moesin) protein that 
links the plasma membrane and the actin scaffolding by crosslinking the actin 
filaments.125  After TCR clustering, Zap-70 is recruited to the raft to act as a 
bridge between the TCR and downstream signaling molecules.126  Coincidentally, 
Zap70 recruitment to rafts is also necessary for the activation and recruitment of 
protein kinase C-βII (PKC-βII) in BCR signaling.126  Several other T-cell 
intermediates are then recruited to the raft fractions after TCR activation 
including CD3ζ chain, SLP76, PKCθ, PLCγ1.101  Both PI3K and CARMA1 
(caspase recruitment domain membrane-associated guanylate kinase 1) are also 
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recruited to rafts in both T- and B-cells.101  Furthermore, the signal attenuating 
tyrosine phosphatase, and transmembrane protein, CD45, is sequestered out of 
the raft membrane upon TCR activation.121  Raft disruption blocked the 
aggregation of TCR and the recruitment of these intermediates ultimately 
inhibiting T-cell activation.  The coordination of positive effecter recruitment and 
negative regulator dismissal through raft organization is necessary to optimize T-
cell signaling.   
 
Immune synapse.  The immune synapse is the site of cell to cell contact 
for both T- and NK cells, and has abundant raft aggregation, allowing optimal 
spatial organization of receptors and signaling intermediates.  Raft aggregation 
promotes the reorganization of the cytoskeleton that is necessary for the 
formation of the immunological synapse.127,128  Raft aggregation and intermediate 
recruitment at the synapse is ultimately responsible for the ability of both the T- 
and NK cells to perform their immunological functions.  Actin filament assembly 
and immune synapse formation in activated T-cells is dependent on the Arp2/3 
complex, Wiscott-Aldrisch syndrome protein (WASp),  the GTPase effecter, 
mammalian homolog of diaphanous formin, mDia1, and the Rho/ROCK/LIMK 
pathway .127,129  Disruption of these pathways result in impaired lipid raft 
formation and limited the ability to form immunological synapses.127  After 
receptor engagement at the immune synapse, rafts are endocytosed, following 
integrin mediated detachment from the substratum, which is also dependent on 
actin polymerization regulated in part by another GTPase Arf6.130  These 
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GTPase activated cytoskeletal rearrangements will be discussed further under 
the GTPases section of this manuscript.  Raft disruption significantly and 
negatively impacts immune synapse fidelity and decreases TCR activity, 
illustrating the importance of rafts in immune response.  It is now well accepted 
that lipid rafts serve as signaling platforms that sequester receptors and 
downstream signaling effectors sequester to facilitate signal transduction for a 
number of receptor pathways, and in diverse cell types.102   
 
Raft mediation of signaling cascades.  Currently there are a number of 
receptor pathways known to be initiated or mediated by rafts, however, the 
question arises, how does this occur?  Currently, there are several suggested 
theories to explain how rafts coordinate receptor signaling, or vice versa, how 
signaling cascades initiate raft aggregation.  First, the affinity of cholesterol and 
signaling intermediates may increase after raft coalescence.113  Alternatively, 
rafts may be induced to coalescence upon protein aggregation at the plasma 
membrane.113  Others suggest that raft activated enzymes may produce water 
soluble phosphor-oligosaccharides that may activate downstream molecules, or, 
that activation and/or aggregation of rafts induces the clustering of GPI-anchored 
proteins, and that these proteins then in turn activate downstream signaling 
molecules.102,105  Regardless of how it is accomplished, it is clear that raft 
activation is important for signal initiation, and that rafts themselves are activated 
and aggregated upon receptor-ligand engagement.   
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Raft Experimentation.  There have been a number of tools used to 
visualize lipid rafts including electron microscopy, fluorescent resonance energy 
transfer (FRET), single particle tracking, immunofluorescence, photonic force 
microscopy, chemical crosslinking, and ultra-centrifugation in sucrose density 
gradients.109,114  The composition of sterols in the lipid raft domains make them 
relatively detergent-insoluble, particularly to Triton-X, at 4°C which allows for their 
isolation and identification.102,106,113  Upon ultracentrifugation in sucrose density 
gradients, the insoluble raft fractions will float to lower density matrices allowing 
for study of both the rafts and their associated proteins.102,106,113  Another useful 
tool in the study of lipid rafts takes advantage of the constituent raft ganglioside, 
GM-1.105  The endotoxin, cholera toxin, from Vibrio cholera, is comprised of 
subunits A and B (CT-B), and CT-B has high affinity for GM-1.105,113,131,132  This 
selective interaction facilitates identification of lipid rafts in a number of assays.  
CT-B may be conjugated to florochromes for GM-1 detection via 
immunofluorescence and flow cytometry, or to horseradish peroxidase for 
western blot detection.  Many of these methods will be described in further detail 
in Chapters 2 and 3 of this manuscript.  Another important feature of lipid rafts is 
the ability to disrupt them with the use of cyclic oligosaccharadides, i.e. 
cyclodextrins.109,133  Cyclodextrins bind to and extract cholesterol from the 
membrane effectively disrupting raft integrity with accompanying loss of all 
associated proteins.  Lipid raft integrity is highly dependent on cholesterol and 
therefore its removal is of bitter consequence to raft fractions.106,133  Beta-
cyclodextrins are the most highly attracted to cholesterol and therefore are most 
45 
 
effective at removing the cholesterol from the plasma membrane.133  Furthermore, 
the solubility of β-cyclodextrins increases by adding methyl groups, and methyl-β 
cyclodextrin (MβCD) is the most commonly used agent for raft disruption.106,133  
Cholesterol intercalating agents, such as nystatin, are alternative although less 
effective disrupting agents.109,113  Instead of removing cholesterol from the 
membrane as is the case with MβCD, nystatin binds to cholesterol in the 
membrane, sequestering it and causing disruption of raft dependent signaling 
cascades.106,134   Nystatin is an anti-fungal with structure similarity to 
amphotericin B, as opposed to an HMG-CoA reductase inhibitor statins that block 
cholesterol synthesis.135 
As mentioned above, GTPases are associated with the raft fractions and 
are important to drive reorganization of the cytoskeleton and as such warrant 
further discussion. 
 
GTPases 
 
Ras superfamily.  The Ras superfamily of GTPases is comprised of 154 
members, grouped into 5 major branches based on sequence similarity, and are 
involved in a number of cellular processes including signal transduction, cell 
cycle regulation, and cytoskeletal reorganization (Figure 7).136  Furthermore, Ras 
GTPases are associated with the lipids in the plasma membrane via 
isoprenylation which is necessary for membrane attachment.137 
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Figure 7.  Ras superfamily.  The Ras GTPase superfamily is comprised of 154 
members that can be grouped into 5 major branches based on sequence 
similarity with 9 additional members.  Some of the cell process regulated by each 
family is provided.   
 
The Ras GTPases are small proteins which shuttle between inactive GDP-
bound states, and active GTP-bound states.136  The transition between GDP-
bound and GTP-bound is accomplished through guanine nucleotide exchange 
factors (GEFs).136  Hydrolysis of GTP back to GDP is accomplished through 
GTPase-activating proteins (GAPs).136  Rho and Rab GTPases are additionally 
regulated through guanine nucleotide dissociation inhibitors (GDI) which can 
block binding of GEFs and GAPs, and prevent the association of the GTPases to 
the plasma membrane (Figure 8).136,138  Gene mutations of proteins that cause 
an upregulation of Ras can be found in about 33% of all human cancers, 
however, mutations of Ras itself are often not observed.136  Most commonly  
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Figure 8.  GTPase regulation.  GTPases switch from inactive GDP bound states 
and active GTP bound states via guanine exchange factors (GEFs) and GTPase 
activating proteins (GAPs).  Rho and Rab GTPases are also regulated by 
guanine dissociation inhibitors (GDI) which prevent GEF and GAP binding to the 
GTPases, and can block association with the plasma membrane. 
 
these activating mutations are found in GEFs and GAPs.136  One of the most 
important functions of the Ras GTPases is reorganization of the actin 
cytoskeleton. 
 
Cytoskeleton.  The actin cytoskeleton performs a number of vital cell 
functions including spatially organizing cellular components, serving as the 
messenger between the intra-and extra-cellular environments, regulating cell 
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movement and shape, and regulating cargo transport throughout the cell.139  The 
cytoskeleton continually accommodates cellular changes based on stimuli 
through reorganization of actin monomers.139  Actin polymerizes to form filaments 
which can be bundled or branch out to form dynamic networks.139  The 
cytoskeleton has three major components; microtubules, actin filaments, and 
intermediate filaments.139  Microtubules  are the stiffest and most complex 
components and are best described in their role in cell division.139  Microtubules 
are unique in the regard that they are either in a state of polymerization or 
depolymerization, but never both simultaneously.139  Interestingly, microtubule 
formation is activated by the GTPase Rac1 which in turn activates the 
polymerization of microtubules creating a positive feedback loop.139  Actin 
filaments are also highly organized, however, are less rigid than microtubules.139  
Actin filaments form a scaffold that is held together by spectrin, forming a 
hexagonal lattice that lies beneath the plasma membrane and allows tethering of 
membrane associated proteins including GTPases.140  Actin filaments are 
important for cytoskeletal reorganization based on external stimuli and are key to 
lipid raft aggregation in response to these stimuli.141  Furthermore, actin filaments 
are involved in the trafficking to and from the plasma membrane, as well as in the 
internalization of ligand bound cytokine receptors.  These processes are all 
regulated by Rho GTPases.142  Both epidermal growth factor (EGF) and platelet-
derived growth factor receptor-β (PDGFR-β) are known to be endocytosed 
through actin reorganization and are dependent on the activity of GTPases.140  
Unlike microtubules, actin filaments are undergoing simultaneous polymerization 
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and depolymerization, allowing constant rearrangement based on environmental 
stimuli.139  Actin filaments continue to polymerize so long as there are available 
monomers suggesting regulation by associated factors such as GTPases.139  
Intermediate filaments are the least rigid components of the cytoskeleton, 
however, they are the most efficient at resisting tensile forces making them 
particularly important for actively circulating cells.139  One of the most well studied 
branches of the Ras family are the Rho GTPases, which in addition to a number 
of other cellular functions, are heavily involved in regulating these actin 
cytoskeleton formations.136   
 
Rho GTPases.  Two of the most highly studied actin cytoskeletal 
structures are stress fibers and membrane ruffles.143  In 1992, Ridley, Hall, and 
colleagues found that the formation of these cytoskeletal elements was induced 
by the activation of the Rho GTPases.143-145  This observation was the first 
suggesting GTPases are involved in regulating cytoskeletal reorganization.  The 
Rho GTPases are comprised of 20 members that can be separated into 8 
families based on sequence similarities (Figure 9).140  The three branches of the 
Rho family known to be involved in action skeleton organization include the Rho-
like family (RhoA, RhoB, and RhoC), Rac-like family (Rac1, Rac2, and Rac3), 
and Cdc42-like, whereas the best studied are RhoA, Rac1, and Cdc42.140,146  
Although there is a high degree of sequence similarity between these proteins, 
they have both overlapping and distinct functions.  Additionally, there is 
substantial crosstalk between them.143  Cytokine signaling induces membrane  
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Figure 9.  Rho GTPase family.  The Rho GTPase family is comprised of 20 
members that can be grouped into 8 subcategories based on sequence similarity.  
The Rac-like, Cdc42-like, and Rho-like families are involved in signal 
transduction and actin cytoskeleton reorganization. 
 
ruffle formation at the leading edge of migrating cells and is controlled by Rho 
GTPases.143  Activation of the actin cytoskeleton by Rho family members is 
critical to a number of cellular processes including cell polarity, cell motility, 
endocytosis, cell cycle regulation, vesicle trafficking, stress fiber formation, and 
focal adhesions.143,147,148  Cytoskeletal reorganization via active Rho GTPases 
has been implicated in cell metastasis and therefore may have a role in disease 
progression.149  Receptor tyrosine kinase (RTK) phosphorylation prefers 
proximity to lipid rafts, and reorganization of the cytoskeleton induces raft 
aggregation and the recruitment of these receptors, processes that are 
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dependent on the GTPases.127  Upon cytokine stimulation, Rho activates lipid raft 
aggregation through the Rho kinases, ROCKI and ROCKII (ROCK).127  ROCK 
phosphorylates LIM kinase (LIMK) which then inactivates cofilin through 
inhibitory phosphorylation.127,150  When cofilin is phosphorylated it is no longer 
able to bind to actin, and thereby, is unable to depolymerize actin filaments, thus 
inducing actin polymerization.150  Rho subfamily GTPases also stimulate actin 
polymerization and stress fiber formation via direct phosphorylation and 
activation of the myosin light chain (MLC) and through ROCK which additionally 
functions to inhibit MLC phosphatase.127,143,147,151  ROCK is also important for the 
migration of macrophages and neutrophils which is accomplished through 
regulation of PTEN.152  Additionally, Rho acts through another GTPase effecter, 
mDia.142,143,147  mDIA is part of the formin family of proteins that are known 
regulators of the actin cytoskeletal.153  Active mDIA promotes actin 
polymerization by promoting binding of monomers to branched ends of filaments 
and is important for the interactions of endosomes and the cytoskeleton.142,143,154  
Interestingly, the gene encoding mDia1, DIAPH1, is located within the commonly 
deleted region of del(5q) and mice lacking DIAPH1 develop a myelodysplastic 
phenotype implicating a role in disease pathogenesis.155,156  In del(5q) MDS, it is 
thought that loss of DIAPH1 inhibits the sensing ability of the actin cytoskeleton 
and somehow promotes the expansion of the del(5q) clones although it is not 
clear how this is done.154  Lastly, Rho actives actin polymerization through WASp 
and Arp2/3 proteins.157  When activated, Rho proteins activate downstream 
signaling effectors and actin skeleton reorganization.140,147    
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Rac GTPases.  The Rac family GTPases are involved in lamellipodia, membrane 
ruffle formation, axon growth, cell adhesion, phagocytosis, and cell 
differentiation.140,143  Rac proteins very actively induce actin polymerization 
through the WASp family protein, WAVE/Scar (Figure 10).143  WAVE/Scar 
activates the Arp2/3 proteins which are responsible for the binding of actin 
monomers to filaments, causing the branching and weblike matrix of the actin 
cytoskeleton.143  Rac activates WAVE through 2 mechanisms; 1) the activation of 
IRSp53, and 2) the forced dissociation of Nap125, PIR121, and/orHSPC3000 
from WAVE/Scar allowing the latter to activate the Arp2/3 proteins.140,143  Rac 
also inhibits the actin depolymerizing protein, cofilin, further inducing actin 
polymerization.140  Rac proteins are responsible for lamellipodium and membrane 
ruffling and extension.140  These likely occur through activation of the DOCK 
proteins.140  Although the Rac proteins have very similar sequences, they seem 
to have distinct roles depending on cell type.140  Rac1 is observed in most cell 
types whereas Rac2 is predominantly expressed in hematopoietic lineages, and 
Rac3 is found mainly in the brain suggesting specific roles of Rac members in 
tissue specific contexts.140   
 
Cdc42.  Cdc42 induces filopodia formation and is involved in cell polarization and 
protrusion.  Additionally, Cdc42 (and Rac1) are involved in cell cycle regulation 
particularly at the G1/S checkpoint, through a MAPK dependent pathway.146,147   
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Figure 10.  Rho GTPase activation of cytoskeletal reorganization.  The Rho 
GTPases regulate actin cytoskeletal reorganization through a number of different 
pathways shown here.   
 
The filopodia formed by Cdc42 are composed of bundles of F-actin and serve as 
“scouts” sensing the cell surroundings and relaying messages to the inside of the 
cell.140  The downstream targets of Cdc42 are WASp (that activates the Arp2/3 
proteins), and mDIA, which induces formation of unbranched actin filaments.   
In summary the Rho GTPases induce actin polymerization and cytoskeletal 
reorganization though a number of mechanisms including activation of actin 
nucleating Arp2/3 proteins, increasing myosin phosphorylation, through ROCK 
which inhibits MLC phosphatase to augment LIMK phosphorylation, and through 
the formin proteins such as mDIA (Figure 10).140,152,158   
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GTPases and hematopoiesis.  The Rho GTPases have key functions in 
hematopoiesis.  Some of the first evidence for this derives from investigations 
showing that HSCs deficient for Rac1 and Rac2 have decreased myelo-and 
erythropoiesis.159  Subsequent studies showed that Rho GTPases regulate HSC 
survival, proliferation, and engraftment in transplantation models.128,146  The Rho 
GTPases also regulate HSC interaction with the bone marrow niche.160  Early 
erythropoiesis in the bone marrow is dependent on Rac1 and Rac2, which are 
responsible for cytoskeletal arrangements in erythrocytes.159,161   The GTPases 
function in erythrocytes via activation of mDia2.159  Furthermore, mDia2 was 
found to be necessary for the maintenance of myeloid homeostasis, while RhoB 
deficiency induces myelodysplasia in mice.155,156  Rac was also found to be 
important for the creation of the actin scaffolding at the plasma membrane in 
erythrocytes.140  Furthermore, Rac GTPases are necessary for erythrocyte 
enucleation via mDia2.160  In their review, Mulloy et al. note that GTPases are 
involved in nearly every step of hematopoiesis and differentiation of all 
lineages.160 
 
Rho GTPases and IMiDs.  Rho GTPases are activated by IMiDs resulting 
in cytoskeletal reorganization.128  IMiD activated RhoA and Rac1 induced 
cytoskeletal reorganization in lymphocytes within minutes, whereas Cdc42 did 
not have similar effects even after extended periods of exposure.128  
Pomalidomide and LEN induced F-actin polymerization was dependent on RhoA 
and Rac1 activity.128  Pomalidomide increased microtubule stabilization and actin 
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polymerization at the apex of migrating cells through ROCK1.128  These effects 
were specific to cell lineages as they were not found in all cell lines tested.128  
However, these reports were the first to indicate that activation of GTPases is a 
biological effect of IMiD treatment.  Although it is now known that the IMiDs 
activate the GTPases, it is not clear how this activation is mediated.  We 
hypothesize here, that actin reorganization via activation of the GTPases after 
IMiD treatment may occur through inhibition of GTPase E3 ubiquitination.   
 
E3 Ubiquitin ligases 
 
Overview.  Ubiquitination is a process by which ubiquitin (Ub), a 76 amino 
acid peptide, is transferred to a lysine residue on a target protein marking that 
protein for a number of cellular processes including intracellular trafficking, gene 
regulation, DNA repair, and proteasomal degradation.162-165  Ubiquitin has 7 
lysine residues that may be used for a number of different ubiquitin chain 
combinations.166  Ubiquitin can be added linearly or may branch out forming 
complex structures, the functions of which are not completely understood (Figure 
11).164  The complex nature, and vast possibilities of Ub chains, may be 
considered as an “ubiquitin code,” which may relay specific signals to target 
proteins directing a number of different outputs.164  Polyubiquitination (occurring 
at lysine 48) of at least four subunits, in general, targets a protein for degradation, 
whereas, mono-, di-, or tri-ubiquitination (on lysine 63) often signals other cellular 
tasks.163,164  Polyubiquitination causes degradation by targeting the protein to the 
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Figure 11.  The ubiquitin code.  The process of substrate ubiquitination targets a 
substrate for a number of cellular processes including gene regulation, DNA 
repair, and proteasomal degradation.  Ubiquitin monomers may be added linearly, 
or may form branched chains.  The sequence and structure of these chains 
marks the substrate for different functions although the exact code is not 
completely understood..   
 
26S proteasome.164,165,167  The 26S proteasome is comprised of 2 subunits, the 
20S proteolytic core and the 19S regulatory unit capping the 20S at both ends.165  
When a ubiquitinated protein is delivered to the proteasome it is de-ubiquitinated 
then unfolded by ATPases at the 19S subunit.165  It is then delivered to the core 
proteolytic subunit where degradation occurs.165  Ubiquitinating complexes are 
composed of three subunits; the ubiquitin-activating enzyme, E1, which uses 
ATP to transfer a ubiquitin molecule to the conjugating enzyme, E2, which acts 
as the donor for the ubiquitin ligase enzyme, E3 that is responsible for the 
transfer of the ubiquitin from the E2 to the substrate receptor.163,164,166,167     
There are two main classes of E3 ligases, HECT (homologous to E6-AP C-
terminus) and RING (really interesting new gene) domain ligases which are 
presumed to have different target motifs.162-164  Currently, there are only about 30 
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known HECT ligases but more than 600 suspected RING domain ligases.166  
Interestingly, there are only two known E1s and less than 40 E2s suggesting the 
E3s are responsible for specificity.163  The major difference between RING and 
HECT E3 ligases, in addition to domain and structure differences, is how they 
transfer the ubiquitin group from the E2 to the substrate receptor (Figure 12).166  
RING ligases directly transfer the ubiquitin from the E2 to the acceptor acting as 
a platform connecting the E2 and substrate.  However, HECT ligases first 
transfer the ubiquitin to an activated cysteine residue on the E3 ligase before 
then transferring it to the substrate.166  Recently, pseudo RING/HECT hybrids 
were identified, that are collectively referred to as  RING-in-between-RING (RBR) 
ligases and will not be discussed in this manuscript.164   
 
 
Figure 12.  E3 ligases.  There are two major groups of E3 ubiquitin ligases.  The 
RING domain ligases act as a platform for the direct transfer of an ubiquitin 
monomer from the E2 to the substrate acceptor.  HECT ligases first transfer the 
ubiquitin from the E2 to an activated cysteine on the HECT ligase, then transfers 
it to the substrate. 
 
E3 ligase regulation.  Regulation of E3 ligases is often accomplished by 
post-translational modification and/or substrate availability.163  Both the E2 and 
E3 subunits may be phosphorylated which is one mechanism by which regulation 
is achieved.163  E3s can also be regulated by specific binding partners, by 
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ubiquitin like peptides, or by small molecules changing the affinity of the E3 for 
either the E2 or target Ub acceptor.163  Additionally, there are about 100 
deubiquitinating enzymes (DUB) that regulate E3 ligase activity by removing 
ubiquitin groups.162,164  Of particular importance is the fact that E3 ligases 
themselves may be ubiquitinated and targeted for degradation either by other E3 
ligases, or in many cases, by auto-ubiquitination.163  Since E3 ligases effect so 
many cellular processes, their regulation is of utmost importance.  As such, 
deregulation of E3 ligases have been linked to a number of human disorders 
including Parkinson’s disease and many different malignancies.163,167   
 
Plasma membrane development and protein turnover.  The 
translocation of plasma membrane machinery and associated proteins are 
controlled by the secretory pathway (which brings components to the cell 
surface) and the endocytic pathway (which is responsible for the internalization 
or recycling of membrane components to the intracellular compartment) both of 
which are controlled in part through ubiquitination complexes.162  Although 
ubiquitination does not seem to play a role in the transport of proteins from the 
ER to the Golgi, it is responsible for the degradation of misfolded ER proteins, 
and plays a role in Golgi sorting.  Any misfolded proteins that escape ER 
degradation, may be marked for degradation by what is known as the Golgi 
complex quality control (GQC) system.162  E3 ligases are also responsible for 
protein transport to the plasma membrane through vesicles, although the exact 
mechanisms are not completely understood.162  There are numerous reports 
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suggesting dependence of endocytosis on ubiquitination, particularly of plasma 
membrane components.162  Both RTKs and GPCRs are endocytosed after 
ligation through endocytic pathways which are dependent on ubiquitination.162  
Upon stimulation these receptors are ubiquitinated triggering their 
internalization.162  The specific roles and specific ligases in endocytosis are not 
fully understood in part due to the number of roles the endocytic pathway 
plays.162  For example, receptor internalization may direct the receptor to be 
either degraded by the proteasome or recycled back to the plasma membrane.162  
In fact, proteins may be sent back to the plasma membrane, sent to the 
proteasome, or sent to the Golgi for recycling.162  Also, not all endocytosed 
proteins are ubiquitinated.162  It is believed that endocytic sorting may involve the 
cooperation between E3 ligases and DUBs, a process that is complicated by the 
fact that internalized plasma membrane proteins can interact with other 
cytoplasmic proteins to promote the formation of new complexes with new 
cellular roles for the recycled plasma membrane component, the E3 ligases 
involved in its internalization, and cooperating effects of the DUBs.162  It is 
believed that when the E3 ligase is associated with ESCRT (endosomal sorting 
complex required for transport), the substrate protein will be bound to the 
lysosome and ultimately for degradation.  However, further studies are necessary 
to confirm these findings.162   
The role of E3 ligases is pivotal to a number of cellular processes 
including regulating components of the plasma membrane and the turnover of 
important signaling receptors.  Although there are hundreds of ubiquitin ligase 
60 
 
complexes, it is important for purposes of this manuscript to further discuss three 
specific RING family members, cereblon, MDM2, and RNF41. 
 
Cereblon.  Cereblon (CRBN) is a 442 amino acid protein that is part of an 
E3 ubiquitin ligase complex that includes Cullin 4, regulator of cullins-1 (Roc1), 
and damaged DNA binding protein-1 (DDB1).39,168  Roc1 and DDB1 form the 
catalytic core of the complex that interacts with E2 enzymes.43  DDB1 also 
connects Cul4 with the substrate.43  The exact role of CRBN in the complex is 
unknown.  CRBN is highly expressed in the human brain and may have a role in 
memory and learning.168  Truncations of CRBN are associated with mental 
retardation.168  Although the importance of CRBN in brain development is not 
new, studies in the last 3 years have shown an important role in IMiD activity.169  
Ito et al. reported that the direct binding target of thalidomide responsible for its 
teratogenic effects, is the CRBN-DDB1 complex.169  The Cul4-E3 ligases are 
known to be important for embryonic development and after more than 40 years 
of investigation, and over 30 different hypotheses, direct biding of thalidomide to 
CRBN is now accepted as the mechanism by which thalidomide induces 
teratogenicity. 39,43,168,169  However, there are likely other factors that contribute to 
teratogenicity since malformations are observed in specific tissues (brain and 
limbs) despite the fact that CRBN is expressed in all cell lineages.43  Interestingly, 
thalidomide is not teratogenic in mice despite 95% sequence similarity between 
human and mouse CRBN, and similar binding affinities of thalidomide and 
CRBN.43  There are a number of hypotheses proposed to explain this including 
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differential breakdown of hydrolyzed byproducts of thalidomide between mice 
and humans, differences in the biological activity of thalidomide, and a lack of 
ROS formation induced by thalidomide in mice due to a stronger anti-oxidant 
response.43 
Direct binding of thalidomide to CRBN causes inhibition of the ubiquitin 
ligase function of the CRBN complex.43,169  In addition to the inhibition of ligase 
activity on substrates, IMiDs also inhibit the auto-ubiquitination ability of CRBN 
further regulating its function.39,168  Recent investigations have implicated CRBN 
in the anti-neoplastic effects of thalidomide and LEN in MM.168,170,171  This finding 
implies that the E3 ligase activity of CRBN is necessary for degradation of some 
regulators important in the maintenance and/or survival of MM cells.168,170,171  
These findings were not specific to thalidomide as both pomalidomide and LEN 
were also found to bind to CRBN, and this interaction was equally as important in 
the anti-proliferative effects in MM cells.170  Not surprisingly, pomalidomide or 
LEN resistant myeloma cells have decreased levels of CRBN.170  The importance 
of these findings is threefold; first, they are the first time a direct biding partner of 
the IMiDs has been identified.  Second, the importance of CRBN in mediating 
varied biological effects of the IMiDs in MM may increase knowledge of MM 
disease biology as well as other hematological malignancies responsive to IMiDs 
such as MDS.  And lastly, the finding that IMiDs can inhibit E3 ligase activity has 
major implications in what is known about the overall biological effects of the 
IMiDs.  
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MDM2.  The murine double minute-2 (MDM2) protein is the major 
negative regulator of p53.172  P53 is well known to be involved in a number of 
cellular processes including cell cycle regulation, apoptosis, DNA repair, and 
senescence.173  MDM2 is capable of negatively regulating p53 by two 
mechanisms.172,173  First, MDM2 binds p53 at the N-terminus of MDM2, thereby 
preventing p53 binding to DNA and preventing transcriptional activity.172,173  
Although, MDM2 blocks p53 binding to DNA, its primary regulation is through 
ubiquitination and ultimately degradation by the proteasome.172,173  Since the 
RING domain is in the C-terminus of MDM2, the two methods by which MDM2 
regulates p53 can be ascertained after a stimulus is provided.172,173  Regulation 
of p53 is of utmost importance as it is upregulated under cytotoxic stress (such 
as genotoxic stress, hypoxia, heat shock or others.)173  However, high levels or 
sustained activation of p53 promotes apoptosis, indicating the need for strict 
regulation and negative feedback.172,173    Interestingly, p53 activates MDM2 
transcription creating its own negative feedback loop.172  When p53 is activated 
by stress it activates MDM2 transcription, MDM2 will then bind to p53 targeting it 
for degradation thereby completing the loop.172,173  In addition to p53, MDM2 
binds and ubiquitinates several other proteins with p53 sequence homology 
including p73, p63, p51, and E2F1 blocking the transactivation of each.172,173  
Although there are a number of E3 ligases that ubiquitinate p53 including the 
HECT E3 ligase, E6AP, Cul4-DDB1 complex, CBP/p300 and others, MDM2 is 
thought to be the primary regulator.173  MDM2 gene overexpression is observed 
in up to 7% of all cancers, with up to 20% of all soft tissue tumors.172  Therefore, 
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MDM2 is a potential therapeutic target for functional interference to stabilize p53 
and induce apoptosis of malignant clones.172  Additionally, the MDM2 homolog, 
MDMX, also ubiquitinates p53 in both an MDM2 dependent and independent 
manner.  MDM2 and MDMX can heterodimerize further regulating their activity in 
p53 degradation.172-174  Both MDM2 and MDMX deficient mouse embryos are 
non-viable.172,173  Interestingly, when p53 was knocked out in MDM2 or MDMX 
embryos, viability of the embryos was restored indicating that the loss of MDM2 
or MDMX caused cell death in a p53 dependent manner.172-174  
 Our laboratory and colleagues recently reported that LEN inhibits the auto-
ubiquitination of MDM2, stabilizing the protein, and promoting the degradation of 
p53.175  In del(5q) MDS, there is accumulation of p53 resulting from nucleolar 
stress and the release of unbound ribosomal proteins in the nucleus.  This results 
from haplosufficiency of RPS14.23  The unbound ribosomal proteins bind to and 
promote the degradation of MDM2 causing an accumulation of p53.  Treatment 
of del(5q) patients with LEN decreased p53 expression, caused by stabilization 
of MDM2 by inhibiting its autoubiquitination function similar to that which occurs 
with CRBN.175 
 
RNF41.  RNF41 [ring finger protein 41, neuregulin receptor degradation 
protein-1 (Nrdp1), fetal liver ring finger (FLRF)] is an E3 ubiquitin ligase that has 
several roles.87  First, it is responsible for the ubiquitination and degradation of 
two additional E3 ligases, BRUCE and parkin.87,176  BRUCE is an inhibitor of 
apoptosis and parkin is known to be associated with disease pathogenesis of 
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Parkinson’s disease.87  RNF41 regulates Toll-like receptor (TLR) signaling via 
ubiquitination of MyD88.87  RNF41 is also involved in the steady state levels of 
cytokine receptors, ErbB3 and ErbB4.87,176,177  RNF41 interacts with these 
receptors independent of ligand binding, ubiquitinates them, and targets them for 
degradation and internalization.87,177  It was also found that RNF41 can regulate 
the steady state membrane expression of other cytokine receptors including IL3 
and EpoR.87  It has since been determined that RNF41 is responsible for Jak2-
associated Type I cytokine receptor ubiquitination and degradation.87  
Furthermore, the regulation of cytokine receptors suggests that RNF41 may also 
be involved in hematopoiesis.  RNF41 overexpression inhibited HSC 
differentiation consistent with decreased levels of EpoR and IL3.176  The role of 
RNF41 in Jak2-associated, Type I cytokine regulation is particularly important for 
this study due to its role in EpoR expression and necessity for steady state 
erythropoiesis. 
 
E3 ligases of GTPases.  Ubiquitination and proteasomal degradation of 
GTPases was not found until 2001.137  As RhoA, Rac1, and Cdc42 are the most 
well studied GTPases, the ubiquitination of these proteins was studied first.  
There are currently two known E3 ligases specific to RhoA and these include the 
HECT ligase SMURF1 (SMAD ubiquitination regulatory factor 1) and CRL3 
complex (Cullin-RING ubiquitin ligase).137,166  SMURF1 activation caused a 
decrease in F-actin polymerization and cell motility suggesting loss of RhoA 
activity.166  Furthermore, loss of Cullin-3 induced actin polymerization in HeLa 
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cells again suggesting its activity of RhoA inhibition.166  Although Cdc42 is 
ubiquitinated and proteasomally degraded, the exact E3 ligases responsible for 
this are not yet known.137,166  The RING ligase Cullin-1 is known to ubiquitinate 
and cause the degradation of two known GEFs of Cdc42, FGD1 and FGD3, and 
therefore it is thought that proteasomal regulation of Cdc42 is accomplished 
primarily through regulating the GEFs and/or GAPs that interact with it.166  
Interestingly, Cdc42 is thought to regulate RhoA expression by binding 
SMURF1.137  Rac1 is also proteasomally degraded after ubiquitination, but the 
ligase responsible was unknown until just recently.137  The HECT E3 ligase, 
HACE1, is responsible for the ubiquitination and degradation of Rac1 and was 
discovered after RNAi-based screening.178,179  HACE1 deletion increased Rac1 
expression, however, had no effect on RhoA or Cdc42. 178,179  Also of interest 
was the fact the HACE1 had a two-fold higher affinity for GTP bound rather than 
GDP bound Rac1 implicating that ubiquitination occurs after activation.178,179  
 The identification of specific E3 ligases of GTPases is still in its infancy 
and further studies should elicit the roles of these ligases in signaling response 
and F-actin reorganization.  We suspect IMiD induced activation of F-actin 
polymerization, lipid raft aggregation, and signal intermediate recruitment is 
accomplished through activation of the GTPases and broad E3 ligase inhibition 
capabilities of the IMiDs, the supporting data of which follows. 
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CHAPTER 2 
Erythropoietin Receptor Signaling is Membrane Raft Dependent 
 
A note to the reader: This chapter has been previously published in the journal 
PLoS One, McGraw et al. 2012. 7(4):e34477, and has been reproduced here with 
permission from the publisher. 
 
Introduction 
Erythropoietin (Epo) is the principal regulator of red blood cell 
production.89,90  Upon Epo binding to its cognate receptor (R), the EpoR 
homodimerizes to initiate activation of the non-receptor tyrosine kinases JAK2 
and Lyn, which in turn phosphorylates the receptor’s cytoplasmic tail and the 
signal transducer and activator of transcription 5 (STAT5).89,90,180  Dimerization of 
phospho (P)-STAT5 enables its translocation to the nucleus and binding to target 
gene promoters, ultimately promoting the expansion, differentiation, and survival 
of red blood cell precursors.89,90,180  The Epo signaling pathway is regulated by a 
balance of phosphatase and kinase activities.180  Lyn kinase has been shown to 
enhance proliferation of erythroid progenitors by increasing colony forming 
capacity and promoting progenitor maturation.181,182  Loss of Lyn inhibits 
activation of STAT5 presumably through activation of negative regulatory 
phosphatases, such as Src homology domain-containing phosphatase-1 (SHP-1), 
SHP-2, and Src homology-2 domain-containing inositol 5-phosphatase 1 (SHIP-
1).183,184  Furthermore, association of Lyn with, and phosphorylation of EpoR and 
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STAT5, promotes activation of downstream signaling.185  Although the signaling 
cascade initiated by Epo and the balance of phosphatase and kinase activity has 
been well studied, the role of receptor localization in the plasma membrane and 
its effect on signal integrity has not been investigated. 
The plasma membrane of hematopoietic cells contains sphingolipid and 
cholesterol enriched microdomains called lipid or membrane rafts.100,186  Lipid 
rafts represent hydrophobic, detergent-insoluble membrane fractions enriched in 
glycolipids and cholesterol.  As a consequence, lipid rafts migrate to low density 
matrices upon gradient centrifugation allowing the isolation of raft membrane 
fractions and associated proteins.105,109  Lipid rafts are specialized membrane 
microdomains that cluster signaling intermediates to create focused signaling 
platforms that facilitate receptor-induced activation of signal transduction 
molecules.  Rafts rapidly coalesce to form aggregates in response to cytokine 
stimulation or integrin engagement to optimize signal transduction.109,187-189  The 
clustering of rafts serves to expose proteins to a membrane environment 
enriched in components that amplify the signaling cascade, including kinases, 
scaffold and adaptor proteins, substrates, as well as redistribution of regulatory 
phosphatases.109,187-189  Recent investigations have shown that raft 
microdomains have a critical role in T-cell receptor, c-kit and integrin signaling, 
protein trafficking, endocytosis, as well as many other diverse cellular 
functions.109,121,122,190-193  In this study, we examined the role of lipid raft 
recruitment in EpoR signaling, receptor interaction with signaling intermediates, 
and EpoR signal integrity.   
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Results 
 
Epo induces raft formation and aggregation.  Lipid raft microdomains 
are characterized by their insoluble nature in non-ionic detergents as well as the 
presence of the constituent ganglioside GM-1 and double acylated proteins such 
as the Src-family kinase and Lyn kinase.  We first investigated whether Epo 
affects membrane raft assembly or raft coalescence by assessing changes in 
membrane fraction distribution of GM-1 and Lyn kinase after Epo stimulation.  
Dot blot analysis of fractionated UT7 cell lysates revealed a greater than 5-fold 
increase of GM-1 in the detergent insoluble raft membrane fractions (fractions 1 
and 2) after Epo exposure (Fig 13A), accompanied by increased raft partitioning 
of Lyn kinase (Fig 13B).   To verify that the detergent insoluble fractions 
represented lipid rafts, we treated cells with a known membrane cholesterol 
chelating agent, methyl-β-cyclodextrin (MBCD), to disrupt raft integrity, and 
examined GM-1 and Lyn partitioning in membrane fractions.  Treatment with 
MBCD abrogated partitioning of either GM-1 or Lyn into the detergent-insoluble 
membrane fractions, consistent with lipid raft distribution (Figs 13A and B).  
In T-lymphocytes, clustering of lipid rafts is an essential step in the formation of 
an immune synapse in response to antigen activation of the T-cell receptor 122.  
To determine if Epo promotes raft coalescence, we quantitated changes in GM-1 
labeled clusters after growth factor treatment.  Raft accumulation in UT7 cells 
after Epo stimulation increased (Fig 13C), accompanied by a significant increase 
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Figure 13.  Epo stimulation induces raft formation and aggregation.  (A) Dot blot 
detection of GM-1 in UT7 cell lysates in non-raft (fractions 5, 6) and raft fractions 
(fraction 2) with corresponding densitometry value in controls, and after Epo or 
MBCD treatment.  Representative blot of at least three independent experiments.  
(B) Western immunoblot of Lyn in raft (R) (fractions 1-2) and non-raft (NR) 
fractions (fractions 4-6). Treatment with Epo increased Lyn kinase incorporation 
into raft fractions, whereas raft disruption by cholesterol depletion with MβCD 
precluded Lyn incorporation. Representative western of at least three 
independent experiments.  (C) Immunofluorescence of UT7 cells showing an 
increase in raft (red) accumulation after Epo exposure.  (D) Immunofluorescence 
of UT7 cells before and after Epo stimulation showing increased raft aggregates 
(red) in the plasma membrane and corresponding quantitation.  (E) 
Immunofluorescence of primary erythroid bursts showing an increase in cellular 
membrane raft fluorescence intensity (red).  Immunofluorescence experiments 
were repeated at least 3 times, representative micrographs displayed. 
 
in the mean number of raft aggregates (4.3 ± 1.4 per cell in untreated controls  
compared to 25.6 ± 3.2 aggregates per cell after Epo stimulation) (Fig 13D; p ≤ 
0.001).  The size of raft aggregates also increased after Epo treatment, with a 
3.33 ± 0.11 fold increase compared to unstimulated controls (p ≤ 0.001).  To 
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verify that the observed changes in raft dynamics in UT7 cells extends to normal 
erythroid progenitors, we assessed raft assembly in bone marrow erythroid 
bursts derived from a normal donor.  BFU-E were isolated by pipetting colonies 
grown in methylcellulose assays after 14 days incubation.  Immunofluorescence 
staining for GM-1 (Fig 13E) showed that mean raft fluorescence intensity in 
primary erythroid progenitors increased 58.4% from 72.79 ± 14/cell in 
unstimulated cells to 115.27 ± 14.22 after Epo treatment (p=0.01).   
 
EpoR co-localizes within lipid rafts.  Recruitment of the T-cell receptor 
into lipid rafts is a dynamic process, triggered by major histocompatability antigen 
engagement .109  To determine if the EpoR co-localizes within raft microdomains 
and is influenced by ligand engagement, we assessed EpoR localization by 
confocal microscopy with and without Epo stimulation.  EpoR rapidly co-localized 
with GM-1 in UT7 cells after Epo stimulation (Fig 14A, rows 1 and 2).  
Translocation of the EpoR to membrane rafts after Epo treatment was also 
confirmed in primary bone marrow erythroid bursts (Fig 14A, rows 3 and 4). 
In addition to  immature erythroid progenitors such as burst forming units 
(BFU-E), colocalization of EpoR in GM-1 raft clusters was also observed in more 
mature, enucleated erythroid cells after Epo stimulation (Fig 14A, bottom row).  
To further illustrate the recruitment of receptor to the rafts, we utilized the power 
of 3D rendering.  Figure 14B is a representative micrograph of an unstimulated 
(left) and stimulated (right) UT7 cell in which the number of rafts is increased 
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Figure 14.  EpoR co-localizes with lipid rafts. (A) Confocal immunofluorescence 
of cells untreated or after Epo stimulation, lipid rafts:red, EpoR:green, 
DAPI/Hoechst:blue. Right panel is a merged image showing lipid raft and EpoR 
co-localization (yellow).  UT7 cells are shown in rows 1 and 2, while human 
primary burst forming units are shown in rows 3 and 4, followed by a maturing, 
enucleated erythroid precursor in row 5.  (B) Three dimensional rendering of UT7 
cells either untreated (left) or after Epo treatment (right).  Top two rows display 
isosurfacing of the rafts (red), EpoR (green), and nucleus (Dapi, blue).  Dapi was 
removed from the middle row to further visualize association of the receptor with 
rafts in the second row of panels.  The bottom row displays volume rendering of 
the same cells to illustrate membrane colocalization (yellow).  (C) Quantitation of 
colocalization in human primary erythroid cells.  Values represent mean ± SE.  
Immunofluorescence experiments were repeated at least 3 times, representative 
micrographs provided. 
 
(red) as well as the recruitment of the receptor (green) to these domains.  The 
bottom row in Figure 14B utilizes volume rendering to emphasize the 
colocalization (yellow) of the rafts and receptor on the cell surface.  We used the 
Pearson’s coefficient to quantitate the percent of colocalization in primary BFU-E 
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cells where there is a significant increase in colocalization after Epo stimulation 
(p = 0.02) (Fig 14C).  EpoR membrane dynamics were further investigated by 
western blot analysis of membrane fractions from UT7 cell lysates isolated by 
gradient centrifugation.  Raft (R) and non-raft (NR) fractions were pooled and 
separated by SDS-PAGE.  EpoR was not detected in lipid rafts from unstimulated 
cells, but was restricted to the membrane and cytosol fractions. After 10 min of 
Epo exposure, the receptor translocated into raft fractions (Fig 14A), confirming 
that EpoR ligand engagement triggers redistribution of the receptor to membrane 
raft microdomains.  To confirm EpoR specificity of antibody immuno-reactivity, 
receptor translocation was confirmed with several commercially available 
antibodies, including the Abcam mouse mAb (MM-0031-6G7) (Cambridge, MA), 
the Abcam goat polyclonal EpoR antibody, and the monoclonal A82 EpoR 
antibody generously provided by Amgen (Thousand Oaks, CA), each of which 
confirmed our findings of ligand induced raft translocation. 80,194-196  Densitometry 
analysis of 2 independent experiments using all 4 of the above mentioned 
antibodies is presented in Figure 15A.  Based on recent investigations validating 
the specificity of the Santa Cruz Biotechnology (Santa Cruz, CA) EpoR antibody 
(M-20), this antibody was used preferentially in subsequent experiments.81  
Furthermore, although Epo signaling is known to diminish after 10 minutes, we 
next investigated an extended range of intervals after Epo stimulation to discern 
the rapidity of receptor translocation into raft fractions (Fig 15B).  EpoR was 
recruited into the raft fractions within 1 minute of growth factor exposure, 
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reaching a peak at 10 minutes, followed by gradual redistribution that was 
completed by 60 minutes. 
 
Epo engagement initiates recruitment of signaling intermediates into 
lipid raft fractions.  Because EpoR was recruited into membrane rafts after 
growth factor stimulation, we investigated subcellular localization of 
corresponding signal effectors to determine if receptor translocation was 
coordinated with effector molecules to form discrete membrane platforms for 
receptor signaling.  Immunostaining of membrane fractions for STAT5, JAK2, Lyn, 
and CD45 showed that Lyn and CD45 were constitutively localized in raft 
fractions in unstimulated cells, whereas JAK2 was absent with minimal detection 
of STAT5 (Fig 15C).  After Epo stimulation, both JAK2 and STAT5 (principal Epo 
signaling proteins) translocated into raft fractions accompanied by an increase in 
Lyn kinase.  However, CD45, a receptor tyrosine phosphatase and key negative 
regulator of EpoR signaling, was excluded from raft fractions and re-partitioned 
entirely into non-raft fractions (Fig 15C).  The differential localization of CD45 
after Epo stimulation suggests that growth factor activation initiates a controlled 
process of raft assembly and aggregation favoring the recruitment of effector 
molecules supporting receptor signal transduction.  Furthermore, we were able to 
show that the activated forms of both Jak2 and Stat5, as well as the alternative 
Epo signaling pathway, MAPK proteins, accompanied EpoR in raft fractions after 
growth factor stimulation (Fig 15D).  
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Figure 15.  Epo stimulation recruits signal effectors into raft fractions.  (A) Raft 
fractions (R) were separated from non-raft fractions (NR) and immunoblotted for 
EpoR to investigate receptor translocation into rafts after Epo stimulation.  
Corresponding quantitation represents the mean ± SE of two independent 
experiments using four different EpoR antibodies.  (B) Raft fractions were 
isolated after stimulation with Epo at the indicated time points and immunoblotted 
for EpoR. Results show that EpoR is recruited into rafts within 1 minute of Epo 
stimulation reaching maximum loading at 10 minutes, followed by gradual 
redistribution thereafter.  Accompanying graphic quantitation of the 
representative experiment.  (C) UT7 cells were starved overnight then treated 
with Epo for 10 min. After fractionation, the non-raft (NR) fractions and raft (R) 
fractions were pooled and immunoblotted for the indicated proteins.  (D) 
Activated forms of Jak2, STAT5, and MAPK were also increased in the raft 
fractions after Epo stimulation.  All westerns were repeated at least in duplicate.  
 
Lipid rafts are required for EpoR signaling.  Given that EpoR activation 
triggers formation of rafts enriched in signal effectors, we next investigated 
whether rafts are necessary for receptor signaling by way of raft microdomain 
disruption.  Cholesterol depletion of UT7 cell membranes with methyl-β-
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cyclodextrin (MBCD) disrupted raft integrity and completely extinguished Epo 
induced phosphorylation of STAT5, the primary downstream transcription factor  
 (Fig 16A).  To determine if secondary Epo signaling pathways were also affected 
by MBCD treatment, we probed UT7 cells for P-MAPK (mitogen-activated protein 
kinase).  Indeed, pretreatment of cells with MBCD abrogated activation of MAPK 
with Epo stimulation.  The PI3K/Akt pathway is not activated by Epo in UT7 cells, 
therefore, to investigate effects on this signaling pathway, we utilized the 
UT7/Epo cell line which displays Akt activation upon Epo stimulation (Fig 16B).  
Pretreatment with MBCD completely extinguished activation of Akt by Epo, 
thereby confirming that all Epo signaling pathways are impaired by raft disruption.  
To verify that MBCD treatment only affected signaling pathways localized to lipid 
rafts, we treated UT7 cells with the cell permeable phorbol 12-myristate 13-
acetate (PMA), which is not directly dependent on membrane receptor activation, 
and induces UT7 differentiation in part through the activation of MAPK.  
Pretreatment of UT7 cells with MBCD prior to PMA stimulation did not affect 
activation of MAPK as evidenced by enzyme phosphorylation (Fig 16C).  These 
data indicate that lipid raft integrity is essential for EpoR signaling, whereas non-
receptor or non-raft signaling pathways are preserved and independent of raft 
integrity.  To confirm that abrogation of EpoR/STAT5 signaling by MBCD is not 
specific to this compound, we repeated the above experiment using the 
cholesterol intercalating agent, nystatin, a less effective but alternative method to 
interfere with raft assembly and dynamics.  Similar to our findings with MBCD, 
treatment with nystatin decreased STAT5 phosphorylation in response to Epo  
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Figure 16.  Raft integrity is necessary for Epo-induced signaling.  (A) UT7 cells 
were starved for 2h then pretreated with MBCD for 30min and stimulated with 
3U/ml Epo for 10min; lysates were immunoblotted with the indicated antibodies.  
(B) UT7/Epo cells were starved for 2h then pretreated with MBCD for 30min and 
stimulated with 3U/ml Epo for 10min.  Lysates were immunoblotted with P-Akt. 
The findings show abrogation of Akt phosphorylation following MBCD 
pretreatment.  (C) UT7 cells were pretreated with MBCD for 30min, then 
stimulated with PMA for 30min.  (D) UT7 cells were starved for 2h then 
pretreated with Nystatin for 30min and stimulated with Epo for 10min. 
Immunoblots for phospho-STAT5, STAT5, and β-actin antibodies with 
densitometry analysis.  All westerns are representative of at least 2 independent 
experiments. 
 
stimulation (Fig 16D); providing further support for the importance of lipid rafts in 
EpoR signal transduction.   
 
Raft disruption attenuates Epo-induced P-STAT5 induction in 
primary erythroid progenitors.  To confirm raft integrity is critical to EpoR 
signaling in primary erythroid progenitors, we next assessed the effect of raft 
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disruption by MBCD on Epo induced STAT5 phosphorylation by flow cytometry in 
bone marrow derived erythroid precursors from a normal donor.  After a 2h 
starvation, BM-MNCs were pretreated with MBCD either with or without Epo.  
Cells were permeabilized and stained with antibodies to CD71, CD45, and 
phospho-STAT5.  Epo-responsive erythroid progenitors were identified by gating 
on the CD45 dim population of CD71+ cells (Fig 17A), and phospho-STAT5 mean 
fluorescent intensity (MFI) was determined (Fig 17B).  Treatment with MBCD 
significantly decreased STAT5 phosphorylation in response to Epo stimulation 
(Fig 5B; P=0.01).  Flow histograms show a marked shift consistent with a marked 
reduction in phospho-STAT5 MFI (Fig 17C).  These findings confirm that 
membrane raft integrity is critical to the fidelity of EpoR signaling in primary 
erythroid precursors. 
 
Recruitment of EpoR into lipid rafts is abrogated by Rac1 and RhoA 
inhibition.  Rho GTPases are key regulators of intracellular actin dynamics, and 
are involved in T-cell receptor trafficking into lipid rafts upon receptor 
stimulation.122  We therefore investigated whether GTPases were also involved in 
EpoR recruitment into membrane rafts after Epo stimulation.  UT7 cells were 
pretreated with a Rac1 inhibitor prior to Epo stimulation, demonstrating that 
inhibition of Rac1 suppressed recruitment of the receptor into raft fractions (Fig 
18A).  We next investigated the effects of RhoA family GTPase inhibition by 
pretreating cells with the Rho-associated protein kinase, ROCK, inhibitor, Y-
27632; again showing that EpoR recruitment was blocked (Fig 18B).  These 
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Figure 17.  Cholesterol depletion attenuates Epo-induced STAT5 
phosphorylation in primary erythroid progenitors.  (A) Bone marrow mononuclear 
cells from a normal donor were isolated then stained with CD71:APC, 
CD45:FITC, and P-STAT5:PE.  CD71Hi/CD45dim cells representing erythroid 
progenitors were gated.  (B) Graphic comparison of geometric mean florescence 
intensities, mean ± standard error from 3 independent experiments.   (C) 
Representative flow histogram showing shift in phospho-STAT5 florescence 
intensity in primary erythroid progenitors treated with Epo with or without MβCD. 
 
findings suggest that Rac1 and RhoA GTPase activation is critical in the 
redistribution of receptor into membrane fraction upon ligand binding. 
 
Discussion  
To our knowledge, these are the first data to provide evidence that the 
EpoR translocates into lipid raft microdomains of the plasma membrane upon 
ligand engagement (Fig 14).  Moreover, receptor recruitment into rafts appears  
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Figure 18.  Recruitment of EpoR into lipid rafts is dependent on Rac1 and RhoA 
GTPase activation.  (A)  Raft fractions were isolated from UT7 cells pretreated 
with 100nM Rac1 inhibitor for 1hr prior to Epo stimulation then immunoblotted for 
EpoR with corresponding quantitation.  (B)  Raft fractions were isolated from UT7 
cells pretreated with 100uM ROCK inhibitor (Y-27632) for 1h prior to Epo 
stimulation then immunoblotted for EpoR with corresponding densitometry 
analysis.  Westerns are representative of two independent experiments. 
 
necessary for EpoR signal fidelity and consequent activation of STAT5.  In 
unstimulated cells, the EpoR resided largely in non-raft membrane fractions, 
which may serve to minimize the potential for ligand-independent interaction with 
signaling intermediates. Upon growth factor engagement, the receptor was 
recruited into lipid rafts accompanied by the incorporation of signaling effectors 
necessary to phosphorylate sites on the receptor tail and initiate signal 
transduction, including both the JAK2 and Lyn kinases, in addition to the principal 
downstream  transcription factor, STAT5 (Fig 15).  Interestingly, CD45, a 
transmembrane protein tyrosine phosphatase that serves to extinguish receptor 
signaling by dephosphorylating JAK2 and the EpoR, was constitutively localized 
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within membrane rafts in unstimulated cells, whereas upon stimulation with Epo, 
re-partitioned exclusively into non-raft fractions.  These dynamic changes in 
CD45 partitioning should serve to optimize receptor signaling upon ligand 
engagement, while restricting the potential for ligand-independent effector 
activation in the absence of the growth factor.  Moreover, these ligand induced 
changes in the redistribution of the EpoR and its effectors appear necessary for 
erythropoietin signal fidelity.  Disruption of rafts by cholesterol depletion 
abrogated Epo-induced STAT5 phosphorylation in both UT7 cells and normal 
erythroid precursors (Figs 16,17), whereas non-receptor initiated activation of 
MAPK by PMA remained intact. Intercalation of membrane cholesterol by 
nystatin treatment also attenuated Epo signaling, indicating that receptor 
integration into rafts is critical and perhaps obligatory for EpoR signaling.  
The subcellular mechanisms responsible for ligand induced changes in 
raft and receptor dynamics may involve G-protein controlled cytoskeletal 
changes. The dependence of EpoR signaling on lipid raft recruitment and 
assembly is analogous to the changes observed in lymphocytes after ligation of 
the T-cell or B-cell receptors.122  Within minutes of ligand engagement of the T-
cell receptor, receptor subunits translocate into lipid rafts from their residence in 
non-raft membrane domains (Figure 15B).  T-cell receptor re-distribution is 
controlled by G-protein coupled actin polymerization involving activation of Rac 
GTPases, a hematopoietic specific member of the Rho superfamily that regulates 
the organization, dynamics and function of the actin cytoskeleton.122,140  
Conditional knock-out of Rac2 was recently shown to block early stages of 
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erythropoiesis in the bone marrow in murine models, suggesting that Rac2 may 
be a candidate molecular regulator of the observed Epo-induced changes in 
membrane dynamics.159,161  Our studies show that inhibition of either Rac1 or 
RhoA GTPases suppresses EpoR translocation into membrane raft domains.  
Defects in GTPase activation therefore could adversely affect receptor signaling 
in select pathologic conditions.  In myelodysplastic syndromes, for example, Rac 
activation is impaired in neutrophils and CD34+ progenitors,197 accompanied by 
impaired lipid raft formation and a corresponding reduction in the generation of 
reactive oxygen species after fMLP stimulation in granulocyte-macrophage 
colony-stimulating factor primed neutrophils.198  Abnormalities in raft assembly in 
erythroid progenitors might also underlie the previously described abnormalities 
in EpoR signaling in MDS which warrants further investigation.49  Overall, our 
findings indicate that ligand engagement of the EpoR initiates dynamic changes 
in raft assembly and composition that bring the receptor and its effectors into 
spacial and temporal proximity within a discrete membrane compartment that 
facilitates activation of the signaling cascade.  Development of strategies that 
enhance raft assembly and EpoR incorporation may be an attractive strategy to 
improve erythropoiesis in hematologic disorders with impaired erythropoietic 
response.   
 
Methods 
 
Reagents and antibodies.  CD71:APC, P-STAT5(Y694):PE, and CD45:FITC 
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 conjugated antibodies used for flow cytometry and anti-CD45 used for western 
blotting were all purchased from BD Biosciences (San Jose, CA).  STAT5, Lyn, 
Akt, P-Jak2, and Jak2 antibodies were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA).  The principal EpoR antibody used in this study 
was purchased from Santa Cruz Biotechnology (M-20).  To confirm immuno-
specificity of EpoR localization (Fig 15A) we also included Abcam mouse mAb 
(MM-0031-6G7), Abcam goat polyclonal, and Amgen (Thousand Oaks, CA) A82 
EpoR antibodies.  ROCK inhibitor, Y-27632 dihydrochloride monohydrate, 
cholera toxin B (CTB) HRP conjugate, methyl-beta-cyclodextran, Nystatin, and 
PMA were purchased from Sigma-Aldrich (St. Louis, MO).  P-MAPK, MAPK, and 
anti-P-STAT5 (Y694) for westerns were purchased from Cell Signaling 
Technology (Danvers, MA).  P-Akt, Alexa Fluor® 488 goat anti-rabbit IgG, and 
Vybrant® Lipid Raft Labeling Kit were ordered from Invitrogen (Carlsbad, CA).  
Recombinant human Epo (Epo) was purchased from Stemcell Technologies 
(Vancouver, BC, Canada).  Rac1 Inhibitor was purchased from EMD Millipore 
(Billerica, MA). 
 
Cell lines and bone marrow cultures.  The human leukemic cell line, 
UT7, was obtained from ATCC (Gaithersburg, MD).  UT7 cells were maintained 
in α-MEM medium supplemented with 20% fetal bovine serum (FBS), 1% 
penicillin/streptomycin solution, and 5ng/ml GM-CSF. UT7/Epo cells were 
maintained in IMDM medium supplemented with 10% FBS, 1% 
penicillin/streptomycin solution, and 1U/mL Epo.  After overnight starvation, cells 
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were stimulated with Epo at a concentration of 3U/mL.  For Rac1 and ROCK 
inhibitor experiments, cells were pretreated for 1h with 100nM and 100uM, 
respectively, before stimulation with Epo.  Low-density mononuclear cell (MNC) 
fractions were isolated from heparinized bone marrow aspirates from healthy 
volunteers purchased from Lonza Walkersville Inc. (Walkersville, MD) using 
standard density gradient centrifugation over Ficoll-Paque Plus (GE Healthcare, 
Little Chalfont, United Kingdom), followed by washing and resuspension in 
Iscove’s Modified Dulbecco Medium (IMDM) supplemented with 10% fetal bovine 
serum, penicillin, and streptomycin.  
Erythroid progenitors at the burst-forming unit–erythroid (BFU-E) stage of 
differentiation were grown in cytokine-defined IMDM, similar to previous 
studies.199  Briefly, 2 X 105 MNC per mL were plated in Complete Methocult® 
medium (StemCell Technologies, Vancouver, BC, Canada) supplemented with 
10% FBS and 3 U/mL erythropoietin.  Plates were incubated at 37ºC in a 5% 
CO2 air mixture in a humidified incubator for 14 days.  BFU-E were identified 
using an inverted microscope, aspirated by pipette, washed twice in PBS then 
resuspended in IMDM for immunofluorescence studies. 
 
Immunoblotting.  Cells were starved in 0.5% FBS containing medium for 
2h prior to 30 min pre-incubation with 10mM MBCD or 50µg/ml nystatin, or 
stimulation with 3U/ml Epo (10 min) or 100ng/ml PMA (30 min).  For RAC and 
ROCK inhibitor experiments, cells were pretreated for 1h prior to Epo stimulation.  
Cells were washed 3x in cold PBS and lysed in 1X RIPA buffer containing 250µM 
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NaVO4, 2µg/ml aprotinin, 2µg/ml leupeptin, 0.2µg/ml pepstatin A, and 500µM 
PMSF.  Sample buffer was added to cell lysates and 100µg of protein was 
separated using SDS-PAGE.  Proteins were transferred to PVDF membranes 
and immunoblotted with the indicated antibodies.  Membranes were developed 
using ECL or ECL Plus according to manufacturer’s protocols (GE Healthcare, 
Piscataway, NJ). 
 
Flow cytometry.  Bone marrow from normal donors was purchased from 
Lonza (Walkersville, MD).  BM-MNCs were isolated using Ficoll-Paque PLUS 
(GE Healthcare, Piscataway, NJ) and starved for 2h in 0.5% FBS containing 
IMDM medium. The cells were then pretreated with 10mM MBCD for 30min and 
stimulated with 3U/ml Epo for 10min.  They were immediately washed 3x in cold 
Staining Buffer (BD Biosciences San Jose, CA), fixed for 10min at 37°C in 
Cytofix (BD), then permeabilized for 30min on ice with Perm Buffer III (BD).  Cells 
were stained with CD71:APC, CD45:FITC, and P-STAT5:PE conjugated 
antibodies.  Cells were washed with Staining Buffer and analyzed on a 
FACScalibur flow cytometer.  Primitive erythroid cells were captured in CD71Hi 
and CD45Dim gated population.  
 
Lipid raft isolation.  Lipid Rafts were isolated as previously 
described.105,198  Briefly, UT7 cells were washed 2x with cold PBS then lysed in 
0.75% Triton X-100 in TNE Buffer [TNE buffer composed of 25mM Tris pH7, 
150mM EDTA, 1mM DTT, 150mM NaCl, and 1 Complete EDTA-free protease 
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inhibitor tablet from Roche (Indianapolis, IN) per 20ml buffer].  Cells were passed 
through a 27G needle several times and incubated on ice for 5min.  Two hundred 
microliters of lysate were mixed with 400µL of 60% Optiprep (Sigma-Aldrich, St. 
Louis, MO) and pipetted into an ultracentrifuge tube.  Decreasing percentages of 
Optiprep ( 35%, 30%, 25%, 20%, and 0%) were loaded on top of each other and 
the tubes were spun at 20000rpm for 20h in a Beckman Coulter (Fullerton, CA) 
Optima L-90K ultracentrifuge.  Fractions were pipetted off one by one and used 
for dot and western blotting. 
 
Dot blots.  Five or ten microliters of fractionated cell lysates were pipetted 
directly onto nitrocellulose membrane.  The membranes were allowed to dry then 
washed briefly in PBS.  They were then blocked in 0.3% Tween20 PBS for 30min 
and incubated in cholera toxin B:HRP conjugated antibody overnight.  The blots 
were washed 3x in 0.3% Tween20 PBS and developed with ECL. 
 
Immunofluorescence.  Starved UT7 cells (0.5% FBS supplemented α-
MEM medium) were stained with Vybrant® Lipid Raft Labeling Kit according to 
manufacturer’s protocol, treated with 3U/ml EPO for 10min at 37°C and fixed with 
Cytofix (BD Biosciences San Jose, CA ) for 10m at 37°C.  Cells were then 
cytospun and stained with EpoR antibody at a 1:50 dilution for 1hr at 37°C, 
washed in PBS and stained 1:500 with Alexa Fluor® 488 goat anti-rabbit IgG for 
1hr at 37°C.  Cells were then mounted using ProLong ® AntiFade reagent with 
DAPI (Invitrogen, Carlsbad, CA) and cover slip placed on top.  Micrographs were 
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taken using a Leica TCS SP5 AOBS Laser Scanning Confocal microscope (Leica 
Microsystems, Germany).  BFU-E colonies isolated from progenitor cultures from 
a normal donor were washed 2X then starved in 0.5% FBS supplemented IMDM 
medium for 2h.  They were then stained with EpoR and Alexa Fluor® 488 goat 
anti-rabbit IgG as above.  The cells were then washed and stained with Vybrant® 
Lipid Raft Labeling Kit according to manufacturer’s protocol.  Cells were 
resuspended in 1ml medium and stained with 1µg/ml Hoechst stain (Invitrogen, 
Carlsbad, CA).   Micrographs of the untreated cells were taken by confocal 
microscopy then 3U/ml of Epo was added to the plate and micrographs from 
stimulated cells were taken 5-20min after Epo treatment.   
 
Immunofluorescence image analysis.  Photomicrographs were obtained 
using a Leica TCS SP5 AOBS laser scanning confocal microscope at zoom 
through a 20X/0.5NA or 63X/1.40NA Plan Apochromat oil immersion objective 
lens (Leica Microsystems, Germany).   405 Diode, Argon 488, and HeNe 543 or 
594 laser lines were applied to excite the flurophores and tunable emissions 
were used to minimize crosstalk between fluorochromes. Gain, offset, and 
pinhole settings were identical for all samples within the treatment group.  Image 
sections were collected at either 0.2 µm (for 3D reconstructions) or at 0.5µm 
were captured with photomultiplier detectors and maximum projections were 
prepared with the LAS AF software version 2.1.0 (Leica Microsystems, Germany).  
In some cases, 4X zoom was applied when acquiring images.  Intensity and 
aggregate analysis were performed using Image Pro Plus version 6.2 (Media 
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Cybernetics, Inc., Silver Springs, Maryland).   Identical threshold settings and 
measurement parameters were used to generate the mean intensity and area 
data.  Aggregates were defined as an object within the cell that has an intensity 
value of at least 20 and an area between 3 and 600 pixels.  Three dimensional 
isosurface renderings were prepared with Imaris software version 5.5.3 (Bitplane 
Inc., Zurich, Switzerland).   
 
Statistical analysis.  Numerical data are expressed as mean ± standard 
error of the mean. Statistical analyses were performed using the Student t test 
(2-tailed for equal variances). P values < 0.05 were considered significant.  
Pearson’s correlation analysis for colocalization was performed using Definiens 
Developer version 1.5 (Definiens AG, Munich, Germany). 
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CHAPTER 3 
Lenalidomide induces Lipid Raft Formation and F-Actin Polymerization 
 
Introduction 
Bone marrow progenitors from patients with MDS display diminished 
activation of STAT5 in response to Epo stimulation despite normal or elevated 
levels of endogenous serum Epo and similar EpoR membrane density compared 
to normal counterparts.49  Our laboratory reported that the EpoR resides within 
plasma membrane microdomains known as lipid, or membrane rafts, which is 
critical to EpoR signal competence (Chapter 2).200  Epo induced the formation 
and aggregation of lipid rafts, as well as the recruitment of key signaling 
intermediates such as EpoR, Jak2, STAT5, and Lyn kinase.  Furthermore, 
receptor engagement of the Epo ligand triggered the translocation of the signal 
attenuating transmembrane tyrosine phosphatase, CD45, to non-raft domains, 
ultimately potentiating signal capacity.200  Disruption of rafts by membrane 
cholesterol depletion inhibited Epo induced activation of STAT5 in both erythroid 
cell lines and primary bone marrow erythroid progenitors, thereby confirming the 
critical role of raft integrity in cellular Epo response.200  Furthermore, inhibition of 
Rho and Rac GTPases, important regulators of the actin cytoskeleton, blocked 
recruitment of EpoR into the raft fractions, indicating a critical role for these 
proteins in the coordination of EpoR membrane domain localization.200  
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 GTPases are activated by immunomodulatory agents (IMiDs) which in turn 
trigger assembly of the immune synapse in T- and NK-cells.127,128  LEN enhances 
erythroid progenitor expansion, potentiates in vitro colony forming capacity in 
response to Epo, and augments Epo induced receptor signaling through 
mechanisms that have not as yet been characterized.46-48  Approximately 75% of 
lower risk, del(5q) MDS patients will respond to LEN acquiring red blood cell 
transfusion independence, hemoglobin normalization, and decrease in the 
del(5q) clone.1,6  This occurs through direct suppression of the del(5q) clone via 
inhibition of the haplosufficient cell cycle regulatory phosphatases, Cdc25c and 
PP2A, resulting in G2/M cell arrest and apoptosis.51  In non-del(5q) MDS, 
erythropoietic rescue occurs in approximately 25% of patients in the absence of 
cytotoxicity to the MDS clone, as evidenced by a decrease in bone marrow 
apoptotic fraction in responding patients, suggesting erythropoietic potentiating 
effect.  In their report, Ebert et al. showed that LEN treatment restored 
expression of the underexpressed erythroid differentiation gene set in responding 
patients, indicating that LEN can improve inherent limitations in EpoR 
transcriptional response in MDS.50  We hypothesize that there is a decrease in 
lipid raft density in MDS patients and that LEN acts at a proximal level in EpoR 
signaling by recruiting signaling intermediates and EpoR into aggregated, active 
signaling raft platforms.  And, that these effects are dependent on the activation 
of the Rho kinase, ROCK. 
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Results 
LEN induces lipid raft formation.  We previously showed that treatment 
of the erythroleukemia cell line, UT7, with recombinant human erythropoietin 
(rhEpo) stimulated rafts within minutes of growth factor exposure.200  We next 
investigated the effects of LEN on raft formation and aggregation.  To assess 
this, we treated UT7 cells with 1µM LEN for 1h.  Lipid rafts were isolated by 
ultracentrifugation and fractions were dot blotted for GM-1 detection (Figure 
19A).  GM-1 is a raft constituent ganglioside and its fractionation and membrane 
localization is used as a marker of lipid rafts.105,131,132  The observed increase in  
GM-1 positive membrane fractions (fraction 2) indicates that LEN treatment 
increased membrane lipid rafts, and this increase was more than that observed 
with rhEpo stimulation (Figure 19A).  To confirm this finding, we next analyzed 
raft aggregation by confocal microscopy in UT7 cells after LEN treatment.  We 
found a marked increase in the number and size of lipid rafts as ascertained by 
GM-1 detection (Figure 19B).  These results demonstrate that LEN is able to 
stimulate raft formation and raft aggregation in the absence of cytokine or 
receptor stimulation. 
 
LEN recruits signal effectors into raft fractions.  Our prior studies 
showed that in addition to inducing raft formation and aggregation, rhEpo 
induced the recruitment of EpoR and signal intermediates Jak2, STAT5, and Lyn  
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Figure 19.  LEN induces the formation of membrane lipid rafts.  (A) Dot blot 
detection of GM-1 membrane fractionation in UT7 cells treated with 1U/ml 
erythropoietin or 1µM LEN for 1hr.  Rafts are located in fraction 2 and non-rafts 
fractions are in 4-6.  (B) Immunofluorescence of UT7 cell rafts in red showing a 
marked accumulation after LEN treatment. 
 
kinase into the raft platforms.  Treatment with rhEpo also sequestered the 
negative regulator and transmembrane protein, tyrosine phosphatase CD45, out 
of the raft fractions, thereby potentiating fidelity of the EpoR signal.  To determine 
whether LEN treatment effected raft constituents, we treated UT7 cells and 
isolated both the raft fractions (fraction 1-3) and non-raft fractions (fractions 4-6) 
after ultracentrifugation (fractions were also confirmed by dot blot, data not 
shown).  These fractions were then probed by western blot (Figure 20).  We 
found that LEN readily induced the recruitment of EpoR into lipid raft fractions 
after 1hr of drug exposure (Figure 20).  We utilized the Santa Cruz (M-20) EpoR  
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Figure 20.  LEN treatment induces recruitment of EpoR and signaling effectors 
into lipid rafts. Western blot of fractionated rafts (red boxes) and non-raft 
fractions.  LEN induces recruitment of EpoR, Jak2, and Stat5 into the raft 
fractions while displacing the negative phosphatase regulator, CD45.  Lyn kinase 
serves as a marker for lipid raft fractionation, although no redistribution was 
observed after LEN treatment. 
 
antibody in these experiments based on previous studies, including ours, 
validating its specificity.81,200  Furthermore, both Jak2 and STAT5 showed 
increased fractionation with GM-1 after LEN treatment indicating recruitment of 
signaling effectors into discrete signaling platforms, similar to that described after 
T-cell activation.109,121,122,200  Additionally, we found that LEN treatment also 
partially redistributed CD45 out of the raft fractions further promoting signal 
efficiency.  Although Lyn kinase fractionation did not change, its partitioning is 
another method by which lipid raft fractions (fractions 1-3) may be ascertained. 
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ROCK inhibition blocks LEN Induced raft formation.  We previously 
demonstrated that rhEpo induction of lipid rafts was dependent on the Rac 
GTPases.  Inhibition of both the Rho kinase, ROCK, and Rac GTPase inhibited 
recruitment of EpoR into the raft fractions after Epo stimulation.  We wished to 
determine whether ROCK was similarly involved in LEN induced raft formation.  
UT7 cells were treated with LEN either with or without pretreatment with 100µM 
ROCK inhibitor, Y-27632, for 30m.  Pretreatment of cells with Y-27632 inhibited 
the induction of lipid rafts by LEN as shown by GM-1 dot blot detection (Figure 
21A).  These data were further confirmed by confocal microscopy (Figure 21B), 
and suggest that the induction of rafts by LEN is dependent on the ROCK kinase. 
 
Figure 21.  LEN induced raft formation is ROCK dependent.  (A) Dot blot 
detection of GM-1 in UT7 cells treated with LEN either with or without ROCK 
inhibitor, Y-27632 (ROCKi), pretreatment.  Rafts are located in fractions 1 and 2, 
while non-raft fractions are 4-6.  (B) Immunoflorescence of rafts (red), nuclei 
(blue), and merged image showing inhibition of LEN induced raft formation with 
ROCKi pretreatment. 
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ROCK inhibition blocks LEN induced F-actin polymerization.  The 
immune synapse in T and NK cells is formed through extensive lipid raft 
aggregation initiated by F-actin polymerization, a process that is regulated by the 
Rho GTPase, ROCK, and LIM kinase (LIMK).127-129  Rho activates actin 
polymerization through the Wiscott-Aldrich Syndrome protein (WASp), which in 
turn activates the Arp2/3 complex proteins that are responsible for promoting 
actin polymerization.157  Furthermore, Rho activates the myosin light chain (MLC) 
promoting actin assembly, while ROCK inactivates the MLC negative regulatory 
phosphatase.127,143,147,151  Lastly, LIMK kinase phosphorylates cofilin.  When 
cofilin is phosphorylated, it is no longer able to bind to actin and prevent 
polymerization.150  Disruption of the Rho/ROCK/LIMK pathways resulted in 
decreased raft accumulation and recruitment of the T-cell receptor, with 
consequent impaired immunological synapses.127-129  We sought to determine 
whether LEN induced actin polymerization in UT7 cells to foster raft assembly 
and whether this process was similarly dependent on ROCK.  Cells were treated 
and stained with phalloidin and analyzed by confocal microscopy (Figure 22).  
LEN treatment induced actin filament polymerization that was inhibited by 
pretreatment with the ROCK inhibitor, Y-27632.  Analogous to the formation of 
the immunological synapse, ROCK dependent F-actin assembly is likely 
responsible for the coalescence of rafts and EpoR signaling components in 
erythroid cells.  
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Lenalidomide induces raft formation in MDS erythroid progenitors.  
Previous reports have shown that fLMP stimulated granulocyte–macrophage 
colony stimulating factor (GM-CSF) primed MDS neutrophils have decreased raft 
density associated with decreased production of reactive oxygen species.198   
 
Figure 22.  LEN induces actin polymerization that is blocked by ROCK inhibition.  
Phalloidin (green) was used to detect actin polymerization.  LEN treatment 
induced actin polymerization, but was inhibited by pre-treatment with ROCK 
inhibitor (ROCKi).  DAPI (blue), last panel is merged image. 
 
Furthermore, Rac activation is reported to be impaired in both neutrophils and 
CD34+ progenitor cells in MDS.197  Therefore, we sought to determine whether 
an impairment in lipid raft assembly limits membrane raft density in primary MDS 
erythroid progenitors to contribute to diminished Epo responsiveness.198  Primary 
bone marrow mononuclear cells were isolated from 11 non-del(5q) MDS patients 
consented on IRB approved research protocols and from 3 normal donors 
96 
 
purchased from Lonza Walkersville.  Cell were treated with LEN then cytospun 
and stained with CD71 and c-Kit antibodies, as well as for lipid rafts.  Erythroid 
progenitor cells were identified as dual CD71 and c-Kit+; the number of raft 
clusters was determined by confocal microscopy.  Mean number of membrane 
raft clusters in MDS erythroid progenitors was decreased compared to normal 
volunteers (p=0.129) (Figure 23).  This deficiency was partially rescued with LEN 
treatment.  Although we did not reach statistical significance, we suspect that if 
we increased the number of samples used, that statistical significance may be 
achieved.  These results provide a novel mechanism of action for LEN in primary 
non-del(5q) MDS cells and warrants study in a larger data set. 
 
 
Figure 23.  LEN induces rafts in deficient non-del(5q) MDS primary erythroid 
progenitors.  Immunofluorescence of raft density in primary normal and non-
del5q MDS bone marrow erythroid progenitors (CD71+, c-Kit+).  DAPI (blue), 
CD71 (green), c-kit (pink), rafts (red).  Primary MDS progenitors show decreased 
raft clusters compared to normal controls, however, raft formation is induced with 
LEN treatment.   
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Discussion 
The data shown here provide new insight as to abnormalities in the EpoR 
signaling platform that may underlie the impaired responsiveness of erythroid 
precursors to Epo in MDS.  We show that EpoR signal fidelity is dependent upon 
proper and adequate lipid raft assembly in the plasma membrane.  In MDS 
erythroid precursors, we found that raft formation is deficient, and importantly, 
that LEN augments Epo-induced erythroid expansion.  Our findings reveal that 
LEN is able to promote lipid raft formation and the recruitment of EpoR into the 
raft microdomains.  Additionally, Jak2 and STAT5 are recruited to the rafts 
compartments while the tyrosine phosphatase CD45 is re-partitioned out of raft 
fractions upon LEN exposure.  LEN induced raft assembly that was dependent 
upon F-actin polymerization, a process which was dependent on the Rho kinase, 
ROCK.  GTPases are known to coordinate reorganization of the actin 
cytoskeleton, which is responsible for raft coalescence and the formation of the 
immune synapse in T-cell activation.127-129     
The actin cytoskeleton has important roles in cell proliferation and 
differentiation, and aberrancies in actin polymerization have been implicated in 
the disease pathogenesis of hematological malignancies.  Recent findings have 
shown that the unconventional Rac activating guanine nucleotide exchange 
factor (GEF), DOCK4, is decreased in MDS patients compared to age-matched 
controls.  DOCK4 is a member of the CDM (C. elegans Ced-5, mammalian 
DOCK180 and D. melanogaster myoblast city) family of proteins which are 
known regulators of adheren junctions and cell migration.  The DOCK4 promoter 
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is hypermethylated in MDS causing gene silencing and decreased protein 
expression.199  Of note, DOCK4 is localized to chromosome 7q31, and deletions 
or translocations involving this site are associated with poor prognosis in MDS 
and AML.  Recent data presented at the 2012 American Society of Hematology 
annual meeting showed that silencing of DOCK4 in MDS was associated with 
diminished F-actin polymerization.203  Furthermore, decreased DOCK4 was 
associated with increased erythrocyte fragility, whereas knockdown of DOCK4 in 
primary progenitor cells led to lineage specific apoptosis of erythroid progenitors, 
features shared by MDS progenitors.  These findings provide a plausible 
pathobiological rationale for the ineffective erythropoiesis in MDS in which 
intrinsic cytoskeletal abnormalities arising from decreased DOCK4 initiated 
polymerization of actin impairs lipid raft assembly and growth factor receptor 
incorporation.  As a consequence, cytokine signal capacity and cell survival are 
diminished.  Rac GTPase dependent raft integrity, which in our investigations is 
partially rescued by LEN, further supports this notion.  The effects of LEN on 
DOCK4 expression and activity warrants further investigation. 
Although LEN is known to activate GTPases, the mechanism by which this 
occurs is unknown.128  Recent findings demonstrate that IMiDs bind to the 
cereblon E3 ubiquitin ligase complex to inhibit ligase function, which appears 
responsible for the teratogenicity of thalidomide as well as the anti-proliferative 
effects of both LEN and thalidomide in multiple myeloma.  Furthermore, we 
recently reported that LEN inhibits the ligase activity of MDM2.204  Inhibition of 
MDM2 auto-ubiquitination stabilizes the protein, permitting binding to and 
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degradation of p53 in del(5q) clones.204  These findings suggest that LEN may 
have broader E3 ligase inhibitory effects.  It is possible that LEN may activate 
GTPases via inhibition of the E3 ligases responsible for their degradation.  
Currently, several ligases are recognized to ubiquitinate RhoA, including SMAD 
ubiquitination regulatory factor 1, SMURF1 and the CRL3 complex (Cullin-RING 
ubiquitin ligase).  The HECT ligase, HACE1, has recently been reported to be 
involved in the ubiquitination and degradation of Rac1.  Additional investigations 
are warranted to determine whether these ligases are also inhibited by LEN.  
These experiments will determine whether E3 ligase inhibition is responsible for 
GTPases activation and consequent actin cytoskeletal reorganization that 
augments EpoR signaling by modulating raft assembly and composition. 
 
Methods 
 
Reagents and cells.  UT7 cells were maintained in alpha-MEM 
supplemented with 20% FBS, 1% penicillin/streptomycin solution, and 5ng/ml 
GM-CSF in a humidified incubator with 5% CO2.  Bone marrow mononuclear 
primary cells were isolated from 11 MDS patients consented on IRB approved 
protocols using Ficoll-Paque (GE Healthcare, Little Chalfont, UK) method and 
from 3 normal donors purchased from Lonza Walkersville Inc (Walkersville, MD).  
LEN was purchased from Fisher Scientific (Pittsburgh, PA).  CT-B:HRP was 
purchased from Sigma-Aldrich (St. Louis, MO)  EpoR, Jak2, Stat5, CD71, c-Kit, 
and Lyn antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, 
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CA).  CD45 antibody was purchased from BD Biosciences (San Jose, CA).  
Secondary antibodies were purchased from Life Technologies Corporation 
(Invitrogen, Carlsbad, CA)  ProLong® Anti-fade reagent with DAPI was 
purchased from Life Technologies (Invitrogen).  ROCK inhibitor, Y-27632 
dihydrochloride monohydrate, was purchased from Sigma-Aldrich. 
 
Lipid raft isolation.  Lipid rafts were isolated as previously described.200  
Briefly, cells were lysed in 0.75% Triton X-100 in TNE buffer [25mM Tris pH7, 
150mM EDTA, 1mM DTT, 150mM NaCl, and 1 Complete EDTA-free protease 
inhibitor tablet from Roche (Indianapolis, IN) per 20ml buffer].  Cells were then 
passed through a 27G needle and left on ice for 5min.  Lysates were then 
pipetted below a decreasing concentration gradient of Optiprep purchased from 
Sigma-Aldrich.  Samples were ultracentriguged at 20000rpm for 20h in a 
Beckman Coulter (Fullerton, CA) Optima L-90K ultracentrifuge.  Fractions were 
pipetted off one by one and used for either western blotting and/or dot blotting. 
 
Western blotting.  Fractions isolated after raft isolation were resolved by 
SDS-PAGE then transferred to PVDF membranes.  The membranes were 
blocked for 30 min in 5% dry milk solution in PBST (PBS with 0.1% Tween 20) 
and incubated with the indicated antibodies.  Membranes were developed using 
ECL or ECL+ according to manufacturer’s protocol (GE Healthcare, Little 
Chalfont, UK).     
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Dot blotting.  Five microliters of each fraction isolated from 
ultracentrifugation was pipetted onto a nitrocellulose membrane.  The membrane 
was then washed in PBS and blocked for 30min in 0.3% PBS-Tween20 solution.  
Membranes were then incubated with CT-B:HRP overnight then washed three 
times in PBS with 0.3% PBS Tween20.  Membranes were developed using ECL 
according to manufacturer’s protocol. 
 
Immunofluorescence.  Raft immunofluorescence was performed as 
previously described.200  Briefly, treated cells were stained with Vibrant Lipid Raft 
Labeling kit (Invitrogen) per manufacturer’s protocol, then cytospun at 450rpm for 
5 min.  Slides were then fixed with BD Cytofix (BD Biosciences) for 10 min at 
37°C.  Slides were washed in PBS and a drop of ProL ong® Anti-fade reagent 
with DAPI was added with a cover slip.   Micrographs were taken using a Leica 
TCS SP5 AOBS Laser Scanning Confocal microscope (Leica Microsystems, 
Germany).  For F-actin staining, cells were treated, then fixed and cytospun.  
Slides were permeabilized in 0.5% Triton-X for 5min at room temperature then 
washed and blocked in 2% BSA-PBS.  Cells were then stained with Alexa Fluor 
488 phalloidin according to manufacturer’s protocol (Invitrogen).  Cells were 
washed, then ProLong® Anti-fade reagent with DAPI was added with a coverslip, 
and micrographs were taken on the Leica TCS SP5 AOBS Laser Scanning 
Confocal microscope.  For the primary cell immunofluorescence experiments, 
rafts were stained as described above.  Before adding DAPI, cells were blocked 
and stained with CD71 and c-Kit antibodies for 1h at room temperature.  Slides 
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were then washed and incubated in secondary antibody (1:1000) for 1hr at room 
temperature.  Micrographs were taken by confocal microscopy.  
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CHAPTER 4 
Lenalidomide Stabilizes EpoR Expression through Inhibition of the E3 
Ubiquitin Ligase, RING Finger Protein 41 (RNF41) 
A note to the reader: Portions of this work have been previously published in 
the journal Blood, Basiorka et al. 2011. 118:2382a and Basiorka et al. 2012 
120(21):3455a, and USF Honors College Undergraduate Thesis, Ashley 
Basiorka, 2012, and have been reproduced here with permissions. 
 
Introduction 
Lenalidomide (LEN), restores defective erythropoiesis and red blood cell 
transfusion independence in approximately 25% of non-del(5q) MDS patients.  Gene 
expression profiling performed by Ebert et. al. showed that LEN responders 
displayed inherently lower expression levels of erythroid specific genes that were 
restored by treatment with LEN.50  Our investigations showed that LEN acts to 
enhance EpoR signal capacity to increase transcriptional response to Epo ligand 
receptor engagement. The latter is achieved at least in part through LEN’s 
potentiating effect on lipid raft assembly accompanied by recruitment of the EpoR 
and key signaling intermediates into the raft microdomains (Chapter 3).   
Recent investigations revealed that both thalidomide and LEN bind to and 
inhibit the function of the cereblon E3 ubiquitin ligase complex, which has been 
implicated in LEN antiproliferative effects in multiple myeloma, and the teratogenicity 
of thalidomide.39,44,168,169  Our laboratory and colleagues recently reported that LEN 
binds to and inhibits the function of another E3 ubiquitin ligase, the murine double 
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minute-2 protein (MDM2).175  LEN inhibits auto-ubiquitination of MDM2 to stabilize 
the protein and foster its binding to and degradation of p53.  Because EpoR turnover 
is regulated by ubiquitination and proteasomal degradation, we evaluated the effects 
of LEN on the E3-ubiquitin ligase, RNF41, which regulates steady state or ligand 
independent, Janus kinase (JAK2) associated Type I receptor internalization.87  We 
hypothesized that LEN upregulates JAK2/EpoR expression through inhibition of 
RNF41, thereby enhancing JAK2 competent receptor signaling. 
 
Results 
 
Lenalidomide upregulates EpoR protein expression.  To determine the 
effect of LEN on EpoR expression, UT7 cells were treated with increasing 
concentrations of LEN for 1hr.  Western immunoblot showed that LEN increased 
EpoR protein expression in a dose dependent manner (Figure 24A).  We next 
treated cells over an extended period and found that upregulation of EpoR after LEN 
exposure doubled within 1hr of treatment (Figure 24B), and continued to increase 
through 8hr of incubation, showing no significant decay as late as after 24 hours of 
drug exposure (Figure 24C, densitometry analysis Figure 24D).  To determine 
whether EpoR upregulation was transcriptionally mediated, EpoR gene expression 
was assessed by real time Q-PCR.  We found no change in EpoR mRNA expression 
after LEN treatment, indicating that receptor protein upregulation is a post 
transcriptional event (Figure 24E).  To investigate whether LEN had similar 
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Figure 24.  LEN increases EpoR expression.  (A) Western blot of UT7 cells treated 
with increasing concentrations of LEN for 1hr showing a dose-dependent increase in 
EpoR expression by the immunomodulatory agent, lenalidomide (LEN).  (B) 
Densitometry analysis.  (C) Western blot of UT7 cells treated with 1µM LEN over the 
indicated time intervals showing an increase in EpoR protein expression as early as 
1hr with continued increase up unitl 8hr after treatment.  (D) Densitometry analysis.  
(E) Relative expression of UT7 EpoR mRNA detected by Q-PCR showing no change 
in transcription indicating that LEN increases EpoR expression at the protein level. 
 
receptor modulating effects in primary erythroid progenitors, bone marrow 
mononuclear cells (BM-MNC) were isolated from three normal donors and changes 
in EpoR expression was assessed by quantitative fluorescence microscopy in 
erythroid precursors identified by CD71 expression (Figure 25A).  We confirmed that 
LEN induced a statistically significant increase in EpoR expression in normal, 
primary erythroid progenitors after 1h of drug exposure (Figure 25B).  Mean  
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Figure 25.  LEN induces EpoR expression in primary erythroid progenitors.  (A) 
Representative immunofluorescent micrographs of three primary normal BM-MNC 
erythroid progenitors.  Erythroid progenitors were identified as CD71+.  Dapi (blue), 
CD71 (green), EpoR (red), and merged image.  (B) Mean fluorescence intensites 
(MFI) +/- standard error showing an increase in EpoR expression in erythroid 
progenitors after LEN treatment (p=0.003).  N=total number of cells analyzed from 
all donors. 
 
fluorescent intensity (MFI) of untreated erythroid progenitors was 1043.5 +/- 32.5 
(SE) vs 1216.6 +/- 51.7 for cells treated with 1µM LEN for 1 hr (p=0.003). 
 
LEN stabilizes EpoR expression.  Our findings that LEN treatment yielded a 
sustained cellular increase in EpoR receptor expression suggested that LEN may 
act through suppression of receptor turnover. To determine whether LEN increased 
the stability of EpoR protein, we first treated cells with cyclohexamide (CHX) to 
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inhibit new protein synthesis.  UT7 cells were treated with 1µM CHX for 24hr either 
with or without LEN (co-treated for 1hr after 24hr CHX pretreatment), and lysates  
collected at the indicated time points over a 72hr period.  Western blot was 
performed to investigate the levels of EpoR at each time point.  Treatment of UT7 
cells with CHX showed approximately a 50% reduction in EpoR expression at 56hr, 
however, addition of LEN markedly extended the half-life of EpoR to beyond 72hr 
(Figure 26).  These data demonstrate that LEN stabilizes the EpoR protein, to 
increase cellular density of signaling competent receptors. 
 
 
Figure 26.  LEN increases EpoR stability.  Western blot of UT7 cells treated with 
cyclohexamide (CHX) either with or without LEN treatment.  Treatment with LEN 
increased EpoR stability changing the half-life from approximatley 56hr to out past 
72hr. 
  
Cytokine receptor induction by LEN is limited to Type I cytokine 
receptors.  To determine if the effects of LEN on receptor turnover are restricted to 
Type 1 cytokine receptors, we examined the effects of LEN on cellular expression of 
IL3-R (Type 1) and c-Kit (Type 2).  LEN upregulated IL3-R expression in a 
concentration-dependent manner, whereas c-Kit expression was unchanged, 
confirming Type 1 receptor specificity (Figure 27). 
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Figure 27.  LEN increases expression of Type I cytokine receptors.  Western blot of 
UT7 cells treated with LEN at increasing concentrations and corresponding 
densitometry values.  LEN increased expression of only Type I receptors (IL3-R and 
EpoR) and had no effect on the Type II receptor, c-Kit, confirming specificity to Type 
I receptors. 
 
LEN inhibits the E3 ubiquitin ligase activity of RNF41.  Recent 
investigations have shown that steady state EpoR turnover is regulated through the 
E3 ubiquitin ligase, RNF41.  RNF41 regulates ligand independent expression levels 
of Jak2 associated, Type I cytokine receptors via substrate ubiquitination and 
targeted proteasome degradation.  We first confirmed that RNF41 bound to 
EpoR/Jak2 complexes after LEN treatment by protein immunoprecipitation (IP) 
followed by EpoR and Jak2 immunoblot (IB).  EpoR:RNF41 binding increased in a 
concentration dependent fashion with LEN treatment (Figure 28A).  Additionally, IP 
of EpoR followed by IB of RNF41 showed similar results (data not shown).  To 
investigate the effects of LEN on RNF41 function, we assessed protein specific 
ubiquitination after proteasomal inhibition with bortezomib followed by LEN treatment.  
IP of RNF41 followed by ubiquitin IB showed that LEN inhibited RNF41 auto-
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ubiquitination in a concentration-dependent fashion, therefore mirroring the effects 
on receptor:RNF41 association (Figure 28B).  Drug inhibition of the E3-ubiquitin 
ligase auto-ubiquitination resulted in cellular accumulation of RNF41 expression with 
corresponding increased association with EpoR and Jak2 (Figure 28A and C), 
paralleling the decrease in EpoR ubiquitination, suggesting that the E3-ubiquitin 
ligase inhibitory effects of LEN extends to RNF41 (Figure 28D).   
 
 
Figure 28.  LEN inhibits RNF41 ubiquitin ligase function.  (A) Immunoprecipitation 
(IP) of RNF41 in UT7 cells treated with LEN at indicated concentrations for 1hr.  
There is a dose dependent increase in co-immunoprecipitation of EpoR and Jak2 
with RNF41 after LEN treatment.  (B) RNF41 was immunoprecipitated then 
immunoblotted (IB) for ubiquitin.  Bortezomib was used to block proteasomal 
degradation.  LEN decreases the ubiquitination of RNF41 in a dose dependent 
manner.  (C) RNF41 protein expression levels increase in total cell lysates of UT7 
cells treated with LEN for 1hr at the indicated concentrations corresponding with 
decreased RNF41 ubiquitination.  (D) Ubiquitination of EpoR decreases with LEN 
treatment [(IP) EpoR, (IB) ubiquitin] via inhibition of RNF41 ligase activity. 
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RNF41 overexpression abrogates LEN-induced upregulation of EpoR.  
To confirm that RNF41 is the principal target of LEN responsible for EpoR 
stabilization, we transfected HEK293T cells with EpoR and/or RNF41 expression 
vectors using the calcium phosphate method.  Steady state EpoR expression 
was lower in EpoR/RNF41 cells compared to cells transfected with EpoR alone 
(Figure 29).  Moreover, EpoR upregulation by LEN was abrogated in 
EpoR/RNF41 cells indicating that cellular RNF41 is a critical determinant of EpoR 
upregulation by LEN. 
 
 
Figure 29.  Overexpression of RNF41 blocks LEN-induced increase in EpoR 
expression.  Western blot and corresponding densitometry analysis of UT7 cells 
transfected with EpoR (pMET7-EpoR) or EpoR and RNF41 (pMet7-RNF41) 
showing a decrease in steady state EpoR, as well as inhibition of LEN-induced 
EpoR, with RNF41 overexpression.  
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RNF41 expression is decreased in LEN responsive MDS primary 
erythroid cells.  To determine the effects of LEN on RNF41 expression in vivo, we 
performed immunohistochemistry on 18 (6 LEN responders, and 12 non-responders) 
bone marrow biopsies from non-del(5q) MDS patients and stained for RNF41 and 
the erythroid marker spectrin (Figure 30A).  By assessing cellular expression profiles 
in bone marrow biopsies obtained before and after LEN treatment, we were able to 
assess the relationship between cellular RNF41 level in erythroid precursors and 
clinical erythroid response.  Relative expression of RNF41 in erythroid precursors at 
baseline was lower in responding patients (non-responder = 0.47 ± 0.03, responder 
= 0.43 ± 0.07, p=0.07) (Figure 30B).  Furthermore, the relative reduction in cellular 
RNF41 expression in erythroids was significantly greater in responding patients 
compared to non-responders (non-responder = 1.06 ± 0.09, responder = 1.11 ± 0.22, 
p=0.05) (Figure 30C).  These results, if validated in a larger data set, suggest that 
cellular RNF41 expression level in erythroid precursors may serve as a predictive 
biomarker for LEN response in MDS.  Moreover, the ability of LEN to reduce 
expression in responding patients may be an important biological marker of 
therapeutic efficacy.  It should be noted that in our in vitro studies, expression of 
RNF41 decreased after 1hr of LEN exposure, however, in our IHC experiments, 
RNF41 levels decreased after extended drug exposure.  As our IHC RNF41 
antibody is reactive to only a small portion of the C-terminus of the protein, it is 
possible that the reactive site may be masked due to binding of RNF41 to other 
proteins, such as Jak2 or EpoR, and should be confirmed with an additional antibody.   
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Figure 30.  RNF41 expression decreases in MDS LEN responders.  (A) 
Representative immunohistochemical analysis of MDS bone marrow biopsies.  
RNF41 is shown in brown and spectrin for erythroid identification is shown in red.  
The relative expression of RNF41 is increased in LEN non-responders (B) and the 
relative reduction ratio significantly decreased in LEN responding patients (p=0.05)  
(C) Furthermore, marked increases of spectrin (red) were observed in responding 
patients (top IHC panel), whereas there was either no change or a decreases in 
spectrin staining in non-responders (bottom IHC panels). 
 
Discussion 
 Our investigations have shown that LEN upregulates the expression of 
signaling competent Jak2 associated receptor complexes in a concentration- 
dependent manner, and that EpoR upregulation is a post-transcriptional event 
yielding accumulation of signaling competent JAK2/EpoR complexes primed to 
augment Epo response.  Inhibition of the E3 ubiquitin ligase activity of RNF41 
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increases EpoR stability and is responsible for LEN induced upregulation of the 
receptor, given that forced overexpression of RNF41 inhibits receptor upregulation.  
Furthermore, cellular expression of RNF41 in bone marrow erythroid precursors in 
patients who responded to LEN treatment was lower as assessed by 
immunohistochemistry.  Moreover, the relative ratio of RNF41 expression 
significantly decreased in responding patients compared to non-responders (p=0.05).  
These data suggest that RNF41 expression in erythroid precursors may be a useful 
biomarker predictive for response to LEN and merits further investigation in a larger 
patient cohort. 
 Our data support the recent findings of LEN inhibition of E3 ligase complexes, 
including cereblon and MDM2.39,168,169,175  Collectively, these data suggest that LEN 
may act as a much broader RING finger E3-ubiquitin ligase inhibitor than originally 
appreciated.  The study of LEN on E3 ligase inhibition should be extended to include 
more proteins including the other major family of ligases, the HECT ligases, since 
direct binding sites of the IMiDs have yet to be clearly determined.  It is possible that 
LEN may be inhibiting ligase function via alteration of the ligase complex or binding 
to the E2 components, and therefore, may not be specific to the RING ligases.  Rac 
GTPases responsible for actin cytoskeletal reorganization and plasma membrane 
compartmentalization, are activated by IMiDs, however, the mechanism is not known.  
Perhaps inhibition of specific ligases that ubiquitinate these GTPases underlies the 
drug activating effects.  Furthermore, E3 ligases are important for cellular transport 
and inhibition by LEN may have a profound effect on the spatial organization of 
cellular machinery.162  Additionally, E3 ubiquitin ligases are important for chromatin 
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remodeling and LEN inhibition on these proteins may have significant effects on 
gene expression.201  Recently, the E3 ubiquitin ligase SMURF2 (Smad ubiquitin 
regulating factor 2) was shown to regulate histone 2B (H2B) ubiquitination, and 
consequently methylation, through inhibition of the RING finger ligase, RNF20.201  
Perhaps LEN inhibits RNF20 to directly alter expression of erythroid differentiation 
genes, or in turn, may inhibit SMURF2 effecting RNF20 expression and gene 
transcription.  As these suggestions are speculative, investigations of more ligases 
(both RING domain and HECT) are warranted, and will provide further insights into 
the molecular mechanisms of this immunomodulatory agent.   
 
Methods 
 
Reagents and Cells.  UT7 cells were grown in alpha-MEM with 20% FBS, 
1 % penicillin/streptomycin solution, and 5 ng/ml GM-CSF.  HEK-293T cells were 
maintained in DMEM supplemented with 10% FBS.  Normal bone marrow 
mononuclear cells were purchased from Lonza Walkersville (Walkersville, MD)  
LEN was purchased from Fisher Scientific (Pittsburgh, PA).  Ubiquitin, IL3-R, c-
Kit, and CD71 antibodies were purchased from Santa Cruz Biotechnology (Santa 
Cruz, CA).  β-Actin antibody was purchased from Sigma Aldrich (St. Louis, MO).  
EpoR and RNF41 antibodies were purchased from Abcam (Cambridge, MA).  
Cyclohexamide was purchased from Sigma Aldrich (St. Louis, MO)  Bortezomib 
was purchased from (Sellechchem, Houston, TX). 
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Western blotting.  Cells were treated as indicated then harvested and 
lysed in 1X RIPA buffer with 250µM NaOV4, 2µg/mL aprotinin, 2µg/mL leupeptin, 
0.2µg/mL pepstatin A, and 500µM PMSF.  Proteins were resolved by SDS-PAGE 
and transferred to PVDF membranes.  Membranes were blocked in 5% dry milk 
PBST solution (PBS with 0.1% Triton X) and incubated with the indicated 
antibody.  Membranes were washed and developed using ECL or ECL+ 
according to manufacturer’s protocol. 
 
Quantitative PCR.  RNA was isolated from UT7 cells using the RNeasy 
Mini Kit (Qiagen, Valencia, CA)  cDNA was generated using High Capcity cDNA 
Reverse Transcription Kit (Life Technology, Applied Biosystems, Foster City, CA)  
per protocol.  ActB and 18S RNA was used as endogenous controls.  EpoR, 18S, 
and ActB mRNA was detected using TaqMan® Gene Expression Assays (Life 
Technology, Applied Biosystems, Foster City, CA).  Real time PCR was carried 
out on an ABI PRISM 7900HT Sequence Detection System with triplicate 
samples using TaqMan® Universal PCR Master Mix with 2 min incubation at 
50°C, then activation of AmpliTaq Gold for 10 min a t 95°C, then 40 cycles of 15s 
at 95°C and 1min at 60°C.  Data was analyzed using SDS software (v2.3)  EpoR 
mRNA was normalized to endogenous controls. 
 
Immunoprecipitation.  Two hundred micrograms of protein from total cell 
lysates were incubated with 2µg of indicated antibody for 2h on ice.  Fifty 
microliters of Protein G Agarose beads (EMD Millipore, Billerica, MA) were added 
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and incubated overnight on a rotator at 4°C.  Bead- lysate slurries were washed 
3x in lysis buffer.  Sample buffer was then added, and beads were dissociated at 
95°C for 5 min.  Proteins were separated by SDS-PAG E and immunoblotted with 
indicated antibodies. 
 
Immunofluorescence.  BM-MNC were treated with 1µM LEN for 1 hr.  
The cells were then cytospun for 5 min at 450rpm.  Slides were fixed in BD 
cytofix for 10 minutes at 37°C for 10min, washed wi th PBS, then blocked in 
2%BSA/PBS for 5min at room temperature (RT).  Cells were then incubated with 
primary antibody (1:50 for EpoR and 1:200 for CD71) for 1hr at RT, washed, and 
incubated in secondary antibody (1:1000) for 1hr at RT.  Cells were washed 
again, DAPI was added, and a cover slip placed on.   Micrographs were taken 
using a Leica TCS SP5 AOBS Laser Scanning Confocal microscope (Leica 
Microsystems, Germany).   Data was analyzed using Image Pro Plus version 6.2 
(Media Cybernetics, Inc., Silver Springs, Maryland). 
 
Transfections.  HEK-293T cells were transfected using the calcium-
phosphate method using pMET7/EpoR and pMET7/RNF41 expression vectors 
kindly provided by Dr. Jan Tavernier from Ghent University (Ghent, Belgium).  
Briefly, cells were transfected with 2µg DNA by the calcium phosphate method.  
Three hours after transfection, medium was changed.  Cells were either 
harvested for expression detection or treated after 48hr. 
 
117 
 
Immunohistochemistry.  Paraffin embedded bone marrow core biopsies 
were deparaffinized  using EZ prep solution (Ventana Medical System, Inc, Oro 
Valley, AZ).  Slides were stained sequentially, first with prediluted spectrin (Cell 
Marque, Rocklin, CA) for 16min followed by secondary for 8min, and was 
demonstrated with red chromagen.  RNF41 secondary antibody (Abcam, 
ab84409) was added (1:400) for 60 min, with secondary incubation of 16min, and 
detection by 3,3' Diaminobenzidine (DAB) chromogen.  Retrieval was done with 
cell conditioning 1 (Ventana Medical Systems, Inc.)  Slides were dehydrated and 
cover-slipped for analysis.  Slides were scanned using AperioTM (Vista, CA) 
ScanScope XT with a 200x/0.8NA objective lens via tri-liner-array. Three regions 
from each slide were manually selected by the study pathologist and extracted 
without compression into Definiens Tissue Studio v3.0 software suite for 
quantitative analysis.  These regional images were segmented using Tissue 
Composer to classify co-localized regions of interest using the red spectrin 
staining as the initial nuclear detection marker.  The cells of interest were 
spectrin positive erythroid cells which also displayed RNF41 staining.  Therefore, 
each nucleus within the regions of interest was identified with a hematoxylin 
threshold of 0.16 and an IHC threshold of 1.  Cytoplasms were grown from the 
nuclei and thresholded into weak, moderate and strong intensity (0.15, 0.28, 0.55, 
respectively).  This complete solution enabled the number of RNF41 positive 
erythroid cells (colocalized staining) to be identified as well as the mean RNF41 
intensity in spectrin positive cells.  Segmented based on the intensity of the 
staining of the various markers, in both nuclear and cytoplasmic areas, where 
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applicable, and classified as erythroid cells within the region of interest based on 
the mean intensity of that cellular object.  The training algorithm was closely 
monitored by the study pathologists and applied to all images representative of 
the patients’ slides. 
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CHAPTER 5 
Discussion 
 
Summary 
In the investigations presented here, we have shown that plasma 
membrane lipid raft microdomains are deficient in MDS, and that EpoR signal 
fidelity is dependent upon its localization within membrane raft fractions 
(Chapters 2 and 3).  We first showed that Epo stimulation induces raft 
aggregation and the recruitment of EpoR with the signaling effectors Jak2, 
STAT5, and Lyn kinase, while CD45, a tyrosine phosphatase negative regulator 
of the growth factor signal, was sequestered outside of raft fractions.  Disruption 
of lipid rafts abrogated Epo signaling, thereby emphasizing the importance of 
lipid raft integrity for EpoR signal competence.  Our subsequent investigations 
identified two mechanisms by which LEN can augment EpoR signaling in MDS, 
1) through promoting the assembly of lipid rafts and their obligatory signaling 
constituents, and 2) EpoR up-regulation.  We showed that LEN induced the 
formation of lipid rafts accompanied by recruitment of EpoR, Jak2, and STAT5, 
while re-partitioning CD45 largely to non-raft fractions independent of ligand 
engagement (Chapter 3).  Induction of raft formation by LEN, and recruitment of 
EpoR by rhEpo, was dependent upon the activity of Rho and Rac GTPases, 
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through regulation of F-actin polymerization and cytoskeletal reorganization 
(Figures 18, 21, and 22).  These findings demonstrate the importance of 
GTPases in LEN’s erythropoietic promoting effects.  GTPases are important 
regulators of hematopoiesis, and their activation by LEN has important 
consequences, not only on EpoR signal fidelity, but also on erythroid survival as 
supported by our prior data showing enhancement of colony-forming capacity.160  
F-actin polymerization triggered by the activation of GTPases by LEN is a key 
effector mechanism regulating lipid raft assembly and aggregation. However, the 
importance of cytoskeletal reorganization prefacing raft assembly warrants 
discussion.  Expression of DOCK4, a gene integral to cytoskeletal regulation is 
decreased in MDS compared to normal progenitors, and is associated with 
decreased F-actin polymerization, increased erythroid fragility, and 
apoptosis.202,203  LEN’s induction of actin cytoskeletal reorganization likely plays 
an important role in enhancing erythroid viability, in addition to priming 
progenitors to augment EpoR signal fidelity by inducing the formation of raft 
signaling platforms, thereby contributing to erythropoietic rescue in responding 
MDS patients. 
The second mechanism by which LEN may augment EpoR signaling is 
through upregulation of EpoR.  We demonstrated that LEN increases EpoR 
expression through inhibition of the E3 ubiquitin ligase activity of RNF41 (Chapter 
4).  LEN inhibits both the auto-ubiquitination of RNF41, and RNF41’s 
ubiquitination of EpoR, thereby increasing receptor stability.  Decreased 
degradation of the Jak2/receptor complex should enhance signaling by 
121 
 
increasing the number of receptors available for membrane translocation and 
ligand binding.  Although erythroid progenitors from MDS patients display 
comparable levels of surface receptors compared to healthy individuals, lipid 
rafts are decreased, which compromises EpoR signal competence.  Moreover, 
an increase in RNF41 would promote Type I receptor degradation, which could 
decrease the number of internalized receptors available for recycling to the 
plasma membrane after growth factor stimulation, thus decreasing the duration of 
Epo induced stimulation.  Furthermore, we found that erythroid expression levels 
of RNF41 prior to treatment with LEN in non-del(5q) MDS responding patients 
was lower than that found in non-responders, whereas the relative reduction ratio 
after treatment was greater in responders than in non-responders (Figure 30), 
suggesting greater receptor stability and Epo responsiveness in responding 
patients.  These results also suggest that RNF41 might serve as a potential 
biomarker predictive for LEN responsiveness in non-del(5q) MDS. 
In summary we have shown two mechanisms by which LEN enhances 
EpoR signaling, 1) through induction of lipid raft assembly accompanied by 
recruitment of the receptor and signal effectors, and 2) through increased protein 
expression and stability of EpoR.  Collectively, these mechanisms serve to 
address primary disturbances in membrane raft/cytokine receptor signaling in 
MDS.  LEN promotes lipid raft assembly, rescues ineffective erythropoiesis, and 
enhances Epo/STAT5 signaling and progenitor survival to correct anemia in 
LEN-responsive MDS patients.  In support of this, the French MDS Group 
recently reported the results of a randomized clinical trial comparing erythroid 
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hematologic response to treatment with LEN alone vs. LEN and epoetin beta in 
transfusion dependent patients with non-del(5q) MDS previously unresponsive to 
Epo treatment.  The results of this study showed that the combined treatment 
significantly improved erythroid response and frequency of transfusion 
independence (23% vs. 40%; p = 0.04) (Abstract #7002, 2013 ASCO Annual 
Meeting, Chicago, IL).  Moreover, recent studies implicate allelic deletion or 
mutation of genes involved in GTPase/cytoskeletal regulation in the 
pathogenesis of MDS.  Examples of this include RhoB, mDia, and Smap1.  
Smap1 is an ARF6 GTPase-activating protein, and loss of the gene causes a 
myelodysplastic phenotype in mice, as well as AML development.204  Loss of 
either RhoB GTPase or its effector, mDIA, similarly causes myelodysplastic 
phenotypes in mice.155,156  These data suggest that novel strategies that promote 
stimulation of Rho or Rac GTPase activation may address a critical abnormality 
in cytokine signaling in MDS. 
 
Future Studies 
There are a number of additional studies that are warranted to delineate 
precise disturbances in raft assembly in MDS, GTPase activity and the 
mechanism(s) by which LEN activates GTPases to effect cytoskeletal changes.  
First, although we and others have shown that the GTPases induce actin 
cytoskeleton reorganization resulting in increased raft or synaptosome formation, 
the specific targets involved in this process are unknown.  Identifying key 
regulatory components in cytoskeletal dynamics could support pharmacologic 
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strategies for development of novel hematopoietic promoting agents.  A summary 
of possible mechanisms involved in the deregulation of the actin cytoskeleton 
that may contribute to the pathogenesis of MDS is provided in Figure 31.  
Currently, there are three GTPases known to regulate the actin cytoskeleton, 
RhoA, Rac1, and Cdc42.  Although RhoA and Rac1 are activated within minutes 
of LEN treatment, the same response is not observed for Cdc42.128  In our 
studies we showed abrogation of LEN induced F-action polymerization by 
pretreatment with a Rac1 inhibitor, and recruitment of EpoR into raft fractions 
was abrogated by both a Rac and ROCK inhibitor, however, the specificity of 
these inhibitors is insufficient to determine the precise GTPases (or GEFs) 
involved, or, whether there are any overlapping functions, or compensatory 
mechanisms.  To address this, additional investigations with knockdown of 
specific proteins are needed.  Although there are 20 Rho family GTPases and 
more than 150 Rac superfamily GTPases, one could begin with the Rac like Rho 
GTPases (Rac1, 2, and 3) known to be heavily involved in hematopoiesis, and 
the Rho-like GTPases (RhoA, B, and C), which are known to be involved in 
cytoskeletal regulation.  Furthermore, to confirm that F-actin polymerization is 
required for lipid raft formation, cells should be treated with a polymerization 
inhibitor in combination with LEN, however, since F-actin polymerization 
inhibitors are extremely cytotoxic, caution should be used in interpreting results 
from such studies. 
We speculate that GTPase activation by LEN may occur through E3 
ubiquitin ligase inhibition, and therefore, after identification of the specific  
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Figure 31.  Cytoskeletal deregulation in MDS.  Deregulation of the actin 
cytoskeleton may occur via a number of different mechanisms including loss of 
Rho GTPase activity, deregulation of DOCK4 by hypermethylation, mutation, or 
deletion, increase in E3 ligase activity resulting in Rho GTPase proteasomal 
degradation, inhibition of either the Rho GTPases and/or Rho kinase, ROCK, by 
micro RNAs, loss of the formin family protein, mDia as in del(5q) MDS, or 
through the Rho regulatory phosphatase, PP2A, which is inhibited by LEN. 
 
GTPases involved in raft formation, targeting ligases responsible for their 
degradation should follow.  At present, there are only three known ligases for 
Rho family GTPases (SMURF, Cul3, and HACE1).  Of these, only Cul3 is a 
RING domain ligase.  Currently, LEN’s ligase inhibitory activity is known to 
extend only to three RING domain ligases (cereblon, MDM2, and RNF41), 
however, the effects of LEN on the HECT ligases should also be investigated.  At 
present, there is only one study suggesting a possible IMiD binding site to CRBN 
(and no data on the binding sites for MDM2 and RNF41, investigations that we 
are currently pursuing), and that site is at the C-terminus of the protein.169  
However, this determination was based solely on site specific point mutations at 
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amino acids 384 and 386, and decreased inhibition of ligase activity by 
thalidomide.  Direct interactions have yet to be validated, and therefore it is 
possible that ligase inhibition may not be specific to RING domain ligases.  
Perhaps, LEN is a broad E3 ligase inhibitor with effects on all ligases.  This 
would particularly hold true for the pseudo-RING/HECT hybrid ligases, which 
have characteristics of both the RING and HECT ligases.  Until the direct binding 
sites of the IMiDs and E3 ligases are determined, the possibility for broad ligase 
inhibition should not be discounted.  Currently, high throughput E3 ligase 
screening assays are available, and these may be utilized to determine whether 
LEN specific ligase inhibition leads to GTPase activation.205 
Additionally, the question of whether lipid rafts are responsible for the 
recruitment and aggregation of EpoR and signaling effectors, or, whether these 
processes are dependent on the receptor itself, merits further investigation.  We 
are currently investigating whether knockdown of EpoR alters LEN’s ability to 
induce membrane raft assembly to determine if receptor expression is necessary 
for raft induction.  Furthermore, since the cereblon complex was the first 
identified target of the IMiDs, the role of cereblon should also be investigated to 
determine its role, if any, in LEN’s promoting effect on raft aggregation and F-
actin polymerization.  Studies utilizing lentivirus knockdown of cereblon are 
underway. 
Another important follow up study should validate the potential of an 
erythroid RNF41 score as a biomarker for response to LEN in non-del(5q) MDS.  
In our preliminary studies, IHC studies were performed on bone marrow biopsy 
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sections from 6 patients who responded to LEN treatment and 12 non-
responders.  Erythroid precursors were identified using the erythroid marker, 
spectrin.  We found decreased baseline expression of RNF41 in the erythroid 
progenitors of responders compared to non-responders that approached 
statistical significance (p=0.07).  We suspect that by increasing the number of 
patients studied, we may obtain statistically significant results.  Furthermore, we 
found that the magnitude of reduction in erythroid RNF41 expression with LEN 
treatment (relative reduction ratio) was greater in responding patients than in 
non-responders, further emphasizing the importance of RNF41 in the response 
to LEN treatment.  LEN’s ability to downregulate RNF41 may be an important 
determinant of the compound’s ability to restore effective erythropoiesis.  In our 
in vitro studies, treatment with LEN increased RNF41 protein expression after 1hr 
of treatment by inhibiting its autoubiquitination.  However, our IHC results 
showed that long term LEN treatment in LEN-responsive MDS bone marrow 
biopsies resulted in a decrease in expression in erythroid progenitors of 
responding patients.  The antibody used for IHC recognizes the C-terminus 
residues 275-317 on RNF41, whereas the antibody used for western 
immunoblots and IP was raised against the full length RNF41, therefore, it is 
possible that the decrease in RNF41 after extended LEN exposure was due to 
masking of the reactive site.  Alternatively extended drug exposure may have 
different biological effects that were not explored in our preclinical studies.  To 
address this, UT7 cells should be treated daily with LEN over an extended period 
of time to determine the long term effect of LEN on RNF41 in vitro.  Additionally, 
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an alternative RNF41 antibody could be used for IHC staining of bone marrow 
specimens that recognizes a different binding region and/or reactivity to the full 
length protein to confirm the observed reduction in expression after long term 
treatment.  Furthermore, we should determine whether EpoR expression 
increased in erythroid precursors in LEN-responsive MDS patients as a 
consequence of RNF41 inhibition, and its relationship to changes in RNF41 
levels.  Lastly, we should determine whether RNF41 expression is increased in 
MDS patients compared to normal controls, as this may provide insight into 
disease biology.   
Previous studies have shown that plasma membrane raft density is 
decreased in stimulated neutrophils from MDS patients.198,206  In our studies, we 
show that lipid raft density is also decreased in MDS bone marrow erythroid 
progenitors, but that lipid raft assembly can be augmented, and all components 
of the EpoR signaling axis can be aligned within lipid rafts through pharmacologic 
stimulation of the cytoskeleton.  The biological abnormalities underlying the 
deficiency in raft assembly in MDS warrants further investigation.  Although 
decreased DOCK4 expression represents one mechanism, additional studies 
should explore whether there is an inherent decrease in Rho GTPase activity in 
MDS stem and progenitor cells resulting in decreased F-actin polymerization and 
lipid raft formation.  DOCK4 is located at 7q31 and may be regulated through 
promoter methylation, mutation, or deletion.202,203,207   Interestingly, chromosomal 
abnormalities at this position are associated with poor prognosis in both MDS 
and AML.208  This could account for ineffective cytokine signaling platforms, 
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decreased EpoR signal fidelity, and decreased erythroid progenitor differentiation 
and proliferation.  As the actin cytoskeleton is closely controlled by the GTPases, 
a deficiency in GTPase activation in MDS progenitors could result in ineffective 
erythropoiesis. This notion is supported by finding that MDS neutrophils have 
decreased Rac activation and decreased F-actin integrity associated with 
decreased DOCK4 expression, as well as evidence of myelodysplasia resulting 
from GTPase and associated protein knockdown.206  Alternatively, mDIA, the 
Rho GTPase effector, is another possible deregulated protein of the cytoskeleton, 
possibly contributing to myeodysplasia.142  The mDIA gene is located at 5q31.3, 
the location of the commonly deleted region in del(5q) MDS, and loss of mDia in 
a mouse model resulted in a myelodysplastic phenotype.155,156  Furthermore, it 
would be of interest to compare lipid raft integrity and aggregation in non-del(5q) 
MDS LEN responders vs non-responders to determine if raft density or dynamics 
in response to drug exposure could serve as a biomarker for drug 
responsiveness.  One would expect that lipid rafts may be decreased in LEN 
responders, and that one mechanism by which therapeutic efficacy is achieved is 
through rescue of diminished raft density as suggested in Figure 23.  Another 
mechanism by which lipid rafts may be diminished in MDS patients is through 
defects in raft manufacturing.  The processing of sphingolipids and cholesterol 
with respect to raft manufacturing in MDS patients should be investigated.  
Defects in either the machinery and/or the translocation of raft components may 
account for the decreased raft density observed in these patients.  This 
hypothesis is supported by decreased expression of an array of genes involved 
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in lipid metabolism in MDS patients.209  Additionally, MDS patients have reported 
decreased levels of serum cholesterol, low-density lipoproteins (LDL), and high-
density lipoproteins (HDL); and the mechanisms responsible for these could 
similarly be responsible for the deficiencies in raft density.210  Although, since 
induction of rafts by LEN occurs within 1hr, there is likely not a defect in 
cholesterol synthesis suggesting alternative mechanisms.  A more likely 
hypothesis is that there are alterations in the distribution of raft components, and 
that this is associated with F-actin polymerization and the cytoskeleton.  It is well 
established that in acute myeloid leukemia (AML), there is high cholesterol 
content in blast cell plasma membranes.211,212  This suggests that there may be 
less available circulating cholesterol available for raft formation and stabilization.  
Furthermore, a change in F-actin polymerization induced by activation of the 
GTPases after LEN treatment could quickly redistribute these molecules to 
create functioning lipid rafts.  Another mechanism by which LEN may upregulate 
the GTPases to induce F-actin polymerization is through inhibition of PP2A.  Our 
laboratory showed that selective cytotoxicity of del(5q) MDS clones by LEN was 
accomplished through inhibition of the regulatory phosphatases, PP2A and 
Cdc25c.51  Rac GTPases, and actin depolymerizing protein, cofilin, are known 
targets of PP2A, inhibition of the phosphatase has been reported to upregulate 
the GTPases and induce F-actin polymerization.213-215  Our laboratory has 
performed preliminary experiments supporting this hypothesis that are depicted 
in Figure 32.  UT7 cells treated with the PP2A inhibitor, cantharadin, showed an 
increase in F-actin polymerization determined by immunofluorescence, an 
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Figure 32.  The PP2A inhibitor, cantharadin, induces F-actin polymerization and 
lipid raft formation.  (A) F-actin polymerization is induced by cantharadin.  
DAPI=blue, F-actin=green.  (B) GM-1 dot blot of UT7 cells either stimulated with 
Epo or treated with cantharadin showing an increase in raft fractions (1 and 2).  
(C) Western blot of isolated fractions showing increasing Lyn fractionation with 
GM-1 after cantharadin treatment. 
 
increase in lipid raft fractionation detected by GM-1 dot blot, and increased Lyn 
fractionation to the raft domains.  However, to validate that PP2A inhibition by 
LEN induced F-actin polymerization through activation of GTPases, gene 
transfected cells lines and appropriate controls should be utilized.  Lastly, the 
cytoskeleton is regulated by microRNAs (miRs) (Figure 31).216  Both the 
GTPases and ROCK are regulated through miRs that potentially may be 
deregulated in MDS.  Some miRs known to regulate the Rho GTPases include 
miR-31, 133, 155, and 185.217-220  In fact, miR-155 is identified to be upregulated 
in MDS CD34+ cells compared to normal counterparts.221  Additionally, the miRs-
138, 184, and 205 are known down-regulators of the Rho kinase, ROCK.222,223  
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Investigation of the role of these miRs in the context of MDS and activation of 
GTPases resulting in cytoskeletal reorganization is warranted.  Ultimately, the 
studies suggested here will provide valuable insight into the disease biology of 
non-del(5q) MDS, as well as the abnormalities underlying impaired raft assembly 
in MDS, thereby offering opportunities for development of novel therapeutics for 
the treatment of patients with MDS.   
 
Implications 
 The implications of the findings presented here extend not only to the 
molecular mechanisms of LEN, and the disease biology of MDS, but also to 
potential biomarkers and novel therapeutic strategies.  For example, we propose 
that RNF41 expression may be used as a biomarker predictive for LEN response 
for MDS patients.  Currently, only about 25% of non-del(5q) MDS patients 
experience a hematologic response to LEN monotherapy, therefore an accurate 
biomarker could significantly improve selection of patients most likely to benefit 
as well as time and cost savings.  Furthermore, lipid raft density and raft 
induction by LEN may be used as markers for response, providing further means 
for patient selection.  Those patients with relatively normal levels of rafts and/or 
low induction of raft aggregation, may be less likely to respond to LEN compared 
to those who have decreased levels of raft density.  Furthermore, if the 
mechanism by which rafts are decreased in MDS can be identified, these 
alterations as well, may provide novel therapeutic targets.  These studies would 
require validation in a prospective treatment trial. 
132 
 
Additionally, small molecules could be used to inhibit the activity of E3 
ubiquitin ligases.  For example, inhibition of RNF41 would lead to an increase in 
expression of EpoR and other Type I cytokines, whereas inhibition of the ligases 
responsible for the degradation of GTPases could induce F-actin polymerization.  
Specific E3 ligase inhibitors would limit the number of off-target effects that would 
be expected from using a broad E3 ligase inhibitor.  Furthermore, if we could 
determine alternative methods for activating the GTPases, i.e., by activating 
GTPases activating proteins (or GAPs), or promoting F-actin polymerization, 
these methods may be useful in restoring effective erythropoiesis in MDS. 
Ultimately, as we gain both disease and drug knowledge, prognosis of 
patients diagnosed with MDS, and other hematologic malignancies, should prove 
to be more promising. 
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